It is made available under a COBBY-IMC-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.11.01.23297926;](https://doi.org/10.1101/2023.11.01.23297926) this version posted November 1, 2023. The copyright holder for this preprint

# $\begin{array}{c} \n\frac{1}{2} \quad \text{if} \quad \frac{1}{2} \quad \text{if} \quad \frac{$ Leveraging large-scale multi-omics to identify therapeutic targets from genome-wide association studies

Authors: Samuel Lessard<sup>+</sup><br>Mathieu Beauvais<sup>3</sup>, Deepa<br>Klinger<sup>7</sup>, Emanuele de Rin<br>**1. Precision Medicir<br><b>2. Estonian Genome** , Michael Chao<sup>1</sup><br>ak K. Rajpal<sup>4a,5</sup>, S<br>aldis<sup>1</sup>, Shameer<br>ne **& Computati**<br>P. Centre, Institu , Kadri Reis<sup>2</sup><br>Srinivas Shai<br>Khader<sup>1\*</sup>, C<br>**onal Biolog**<br>te of Genor , FinnGen,<br>nkara<sup>1</sup>, Jen<br>lément Ch<br>**y, Sanofi L**<br><mark>nics, Univ</mark> mifer Sloane<sup>6</sup>, Priit Palta<sup>2</sup>, Katherin<br>atelain<sup>1\*</sup><br>JS, Cambridge, MA, USA<br>ersity of Tartu, Tartu, Estonia Mathieu Beauvais<sup>3</sup><br>Klinger<sup>7</sup>, Emanuele<br>**1. Precision P<br>2. Estonian G<br><b>3. Digital R&I** , Deepak K. Rajpal<sup>au,s</sup>, Srinivas Shankara<sup>4</sup><br>de Rinaldis<sup>1</sup>, Shameer Khader<sup>1\*</sup>, Clémen<br>Medicine & Computational Biology, San<br>ienome Centre, Institute of Genomics, L<br>D Data & Computational Sciences, Sano , Jenniter Sloane<sup>v</sup><br>it Chatelain<sup>1\*</sup><br>ofi US, Cambridg<br>Jniversity of Tart<br>fi, Chilly-Mazarin , Priit Palta<sup>2</sup><br>e, MA, USA<br>u, Tartu, Est<br>, France ,<br>,<br>.<br>ania Klinger'<br>1.<br>2.<br>3.<br>4.

- 
- Emanuele de Rinaldis<sup>+</sup><br>Precision Medicine & C<br>Estonian Genome Cent<br>Digital R&D Data & Co<br>Translational Sciences, , Shameer Khader\* , Clément Chatelain\*<br>Computational Biology, Sanofi US, Cambi<br>Ire, Institute of Genomics, University of T<br>mputational Sciences, Sanofi, Chilly-Maz<br>Sanofi US, Framingham, MA, USA 1. Preminim Medicine Medicine Medicine (1997) Samon 23, Samoning J, Ma, 2011<br>2. Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Est<br>3. Digital R&D Data & Computational Sciences, Sanofi, Chilly-Ma
- 2. Digital R&D Data & Computational Sciences, Sanofi, Chilly-Mazarin, France<br>2. Translational Sciences, Sanofi US, Framingham, MA, USA<br>3. Pre-Clinical and Translational Sciences, Takeda, MA, USA<br>3. Immunology & Inflammatio
- 
- 
- 3. Digital Republic Paraceter, Paraceteric Paraceteric y Paraceteric y Computational<br>3. Differential Rad Translational Sciences, Takeda, MA, USA<br>3. Immunology & Inflammation Development, Sanofi US, Cambridge, MA, USA<br>3. Ge 5. Pre-Clinical and Translational Sciences, Takeda, MA, USA<br>6. Immunology & Inflammation Development, Sanofi US, Ca<br>7. Genetics Research, Sanofi US, Cambridge, MA, USA 5. Immunology & Inflammation Development, Sanofi US, Ca<br>7. Genetics Research, Sanofi US, Cambridge, MA, USA<br>8. Employee of Sanofi US at the time of study
- 6. Immunology & Inflammation Development, Sanofi US, Cambridge, MA, USA<br>7. Genetics Research, Sanofi US, Cambridge, MA, USA<br>8. Employee of Sanofi US at the time of study<br>\*These authors contributed equally
- a. Employee of Sanofi US at the time of study<br>\*These authors contributed equally<br>\*These authors contributed equally  $\ddot{\phantom{0}}$

a. Employee the Sandwick of Sandwick School of Sandwick School of Sandwick School of Sandwick School of School<br>The Sandwick School of School<br>T



 $\begin{array}{c} \n\frac{1}{2} & \frac{1}{2} \\ \n\frac{1}{2} & \frac{1}{$  MACKGROU<br>BACKGROU<br>studies (GV<br>identify link<br>association 1 BACKGROUND: THERAPEND: THERAPPORT PRESSUPP PRESSUPP PRESSUPP PRESSUPP THERAPPORT SUPPORT SUPPORT SUPPORT SUPPORT<br>1 BACKGROUND: Interaction, induction, independence from general associations identified in GWAS remains cha 2 studientify links between genetic variants and phenotypic variation; however, identifying the genes drivers associations identified in GWAS remains challenging. Integration of molecular quantitative trait loci (molQTL) s 3 identified in GWAS remains challenging. Integration of molecular quantitative trait loci<br>3 (molQTL) such as expression QTL (eQTL) using mendelian randomization (MR) and colocalization<br>3 analyses can help with the identif 4 and 10 associations in the community of the galaxies of mological parameters (mological parameters)<br>
4 analyses can help with the identification of causal genes. Careful interpretation remains warranted<br>
1 because eQTL c 5 (molder) such a constant and the identification of causal genes. Careful interpretation remains warrante<br>
17 (because eQTL can affect the expression of multiple genes within the same locus. **METHODS:** We<br>
18 (colocalizat 6 because eQTL can affect the expression of multiple genes within the same locus. METHODS: We use<br>
combination of genomic features that include variant annotation, activity-by-contact maps, MR, ane<br>
colocalization with mol 2 combination of genomic features that include variant annotation, activity-by-contact maps, MR, and<br>2 colocalization with molQTL to prioritize causal genes across 4,611 disease GWAS and meta-analyses<br>2 from biobank studie 8 colocalization with molQTL to prioritize causal genes across 4,611 disease GWAS and meta-analyses<br>8 from biobank studies, namely FinnGen, Estonian Biobank and UK Biobank. RESULTS: Genes identified<br>8 is using this approac From biobank studies, namely FinnGen, Estonian Biobank and UK Biobank. **RESULTS**: Genes identified<br>using this approach are enriched for gold standard causal genes and capture known biological links<br>between disease genetics 11 using this approach are enriched for gold standard causal genes and capture known biological links<br>12 between disease genetics and biology. In addition, we find that eQTLs colocalizing with GWAS are<br>13 statistically enr 12 between disease genetics and biology. In addition, we find that eQTLs colocalizing with GWAS are<br>13 statistically enriched for corresponding disease-relevant tissues. We show that predicted directiona<br>14 from MR is gene 12 between any of the and biology. In addition, we find that the set of that any distribution from MR is generally consistent with matched drug mechanism of actions (>78% for approved drug Compared to the nearest gene mapp 14 from MR is generally consistent with matched drug mechanism of actions (>78% for approved drugs).<br>15 Compared to the nearest gene mapping method our approach also shows a higher enrichment in<br>16 approved therapeutic tar 15 Compared to the nearest gene mapping method our approach also shows a higher enrichment in<br>16 approved therapeutic targets (risk ratio 1.38 vs 2.06). Finally, using this approach, we detected a nove<br>17 association betwe 16 approved therapeutic targets (risk ratio 1.38 vs 2.06). Finally, using this approach, we detected a r<br>17 association between the IL6 receptor signal transduction gene IL6ST and polymyalgia rheumatica,<br>18 indication for 17 association between the IL6 receptor signal transduction gene IL6ST and polymyalgia rheumatica, an<br>18 indication for which sarilumab, a monoclonal antibody against IL-6, has been recently approved.<br>19 **CONCLUSIONS**: Com 17 association between the IL6 receptor signal transduction gene IL6ST and polynyalgia rheumatica, and<br>18 indication for which sarilumab, a monoclonal antibody against IL-6, has been recently approved.<br>19 **CONCLUSIONS**: Co 19 **CONCLUSIONS**: Combining variant annotation and activity-by-contact maps to molQTL increases<br>18 performance to identify causal genes, while informing on directionality which can be translated t<br>18 successful target iden 19 CONCLUSIONS: CONCLUSIONS: CONCLUSIONS: CONCLUSIONS: CONCLUSIONS: CONCLUSIONS: CONSIDERATIONS: CONSIDERATION<br>19 Dependence to identify causal genes, while informing on directionality which can be translated to<br>19 Success 21 successful target identification and drug development. 21 successful target identification and drug development.

 $\overline{2}$ 

|
|
|

22 CHER ALTIN TERNATION MATTEL CHARGED AND THE MATTEL AND THE MATTEL, THE MATTEL AND MATTEL SUBSEMBLE AND MATTEL<br>22 BACKGROUND<br>25 Genome-wide associations studies (GWAS) have been successful in identifying genes associated 24 **BACKGROUND**<br>25 Genome-wide associations studies (GWAS) have been successful in identifying genes a<br>26 traits, diseases, and molecular phenotypes. [1, 2] Discoveries from GWAS have increase<br>27 over the vears due to low

25 Genome-wide<br>26 traits, diseases,<br>27 over the years d<br>28 cohorts, and me 22 traits, diseases, and molecular phenotypes. [1, 2] Discoveries from GWAS have increased substantially<br>27 over the years due to low cost of genomic profiling technologies, an increased number of studies, larg<br>28 cohorts, 27 over the years due to low cost of genomic profiling technologies, an increased number of studies, large<br>28 cohorts, and meta-analyses, as well as the formation of deeply phenotyped datasets.[3] The later<br>29 include larg

28 cohorts, and meta-analyses, as well as the formation of deeply phenotyped datasets.[3] The later<br>29 include large-scale biobank projects such as UK Biobank (UKB)[4, 5], Estonian Biobank[6], and<br>30 FinnGen.[7] As an exam 29 include large-scale biobank projects such as UK Biobank (UKB)[4, 5], Estonian Biobank[6], and<br>20 FinnGen. [7] As an example, the UK Biobank alone has contributed to over 3,200 publications<br>21 (https://www.ukbiobank.ac.u 29 Include large-scale biology include the statement (1994), 200 include such an example, the UK Biobank alone has contributed to over 3,200 publications<br>31 (https://www.ukbiobank.ac.uk/enable-your-research/publications), 31 (https://www.ukbiobank.ac.uk/enable-your-research/publications), and the FinnGen project<br>32 increase the number of discoveries emerging from rare variants enriched in the Finnish popu<br>33 Similarly, the Estonian Biobank,

32 increase the number of discoveries emerging from rare variants enriched in the Finnish population.[7]<br>33 Similarly, the Estonian Biobank, with its extensive dataset, has enhanced rare and low-frequency gene<br>34 variation Similarly, the Estonian Biobank, with its extensive dataset, has enhanced rare and low-frequency genet<br>variation discoveries [8-10]<br>Discoveries from genetic studies provide a highly valuable resource for drug discoveries. 34 variation discoveries.[8-10]<br>35 Discoveries from genetic studies provide a highly valuable resource for drug discoveries. For example,<br>36 therapeutic targets with genetic support are >2 times more likely to succeed in c 35 Discoveries from genetic studies<br>36 therapeutic targets with ger<br>37 notable example is the asso<br>38 Crohn's disease, suggesting 35 therapeutic targets with genetic support are >2 times more likely to succeed in clinical trials.[11, 12] A<br>37 notable example is the association between a loss-of-function missense variant in *IL23R* gene and<br>38 Crohn's 37 notable example is the association between a loss-of-function missense variant in IL23R gene and<br>38 Crohn's disease, suggesting that IL-23 blockage could be beneficial.[13-16] Drugs targeting the IL-23<br>39 receptor inclu 38 Crohn's disease, suggesting that IL-23 blockage could be beneficial.[13-16] Drugs targeting the IL-2<br>39 creeptor including Ustekinumab and Risankizumab have recently been approved by the FDA for th<br>39 treatment of Crohn 39 receptor including Ustekinumab and Risankizumab have recently been approved by the FDA for the<br>30 treatment of Crohn's disease following successful clinical trials.[17-19] Other notable examples of<br>31 targets supported 39 treatment of Crohn's disease following successful clinical trials.[17-19] Other notable examples of<br>39 targets supported by GWAS include *IL6R* for rheumatoid arthritis (Sarilumab, Tocilizumab) and *HMG*<br>32 for high lev 14 transfer of Croatinum and the Crossing successful clinical trials. (Sarilumab, Tocilizumab) and HM<br>142 tor high levels of low-density lipoprotein (statins).[20, 21]<br>143 While these examples clearly show that disease-ass

41 targets supported by GWAS include IL6R for rheumatoid arthritis (Sarilumab, Tocilizumab) and TMGCR<br>42 for high levels of low-density lipoprotein (statins).[20, 21]<br>43 While these examples clearly show that disease-assoc 43 While these examples clearly show that disease-associated<br>development, it remains a challenge to accurately assign c development, it remains a challenge to accurately assign causal genes driving disease-risk from GWAS<br>development, it remains a challenge to accurately assign causal genes driving disease-risk from GWAS  $44.44$  development, it remains a challenge to accurately assign causal genes driving disease risk from GWAS assign causal  $3$ 

r<br>i 45 most variants identified in GWAS fall in non-coding regions of the genome.[22-24] While it's been 47 influence traits over large genomic distances.[25] In addition, this observation may be biased towards<br>48 genes that have been well-characterized because they fall at the center of genetic association<br>49 signals.[26]<br>50 17 Influence traits over large general antition-pay in addition, the enter of genetic association<br>18 genes that have been well-characterized because they fall at the center of genetic association<br>19 Signals.[26]<br>19 Several

signals.[26]<br>Several approaches have been used to predict causal genes, including selecting the nearest ge<br>pathogenicity predictions, epigenetic interactions, and integration of molecular quantitative tr<br>(molQTL) such as e 50 Several approximations of the Marian State St 51 pathogenicity predictions, epigenetic interactions, and integration of molecular quantitative trait loci<br>52 (molQTL) such as expression QTL (eQTL). Mendelian randomization (MR) integrating GWAS and molQTL<br>53 can help id 52 (molQTL) such as expression QTL (eQTL). Mendelian randomization (MR) integrating GWAS and molQ<br>53 can help identify causal relationships while informing on directionality but may be confounded due to<br>54 linkage disequil For the protein and the control of the informing on directionality but may be confounded due to<br>
linkage disequilibrium (LD). [27-29] On the other hand, colocalization approaches can be used to detect<br>
whether molQTL and G 54 linkage disequilibrium (LD). [27-29] On the other hand, colocalization approaches can be used to detections<br>55 whether molQTL and GWAS signals share a common causal variant in a specific locus.[30, 31] While<br>56 colocali whether molQTL and GWAS signals share a common causal variant in a specific locus.[30, 31] While<br>colocalization approaches can link genetic variation to changes in gene expression in specific tissue or<br>cell-type contexts, 55 colocalization approaches can link genetic variation to changes in gene expression in specific tissue of<br>57 cell-type contexts, they also tend to be pleiotropic and often impact the expression of multiple gene<br>58 within 57 cell-type contexts, they also tend to be pleiotropic and often impact the expression of multiple genes<br>58 within the same locus. [26, 32, 33] They can also impact expression across multiple tissues and cell<br>59 types, de 58 within the same locus. [26, 32, 33] They can also impact expression across multiple tissues and cell<br>59 types, decreasing their utility to identify pathogenic cell types. [32, 34, 35] In addition, a large fraction<br>60 GW types, decreasing their utility to identify pathogenic cell types.[32, 34, 35] In addition, a large fractic<br>60 GWAS loci don't show eQTL signals, potentially due to the unavailability of data for relevant cell typ<br>61 speci 59 STEER ON THE UNITY PERSON CONSUMED TO SPECIES TO SERVICE THE UPPER ON SERVICE OF SPECIES OF SPECIES.<br>
59 Splicing.[32, 36, 37] Despite these c specific biological contexts or variants affecting disease risk due to different mechanisms such as<br>splicing.[32, 36, 37] Despite these challenges, eQTL have successfully been used to identify causal<br>genes.[38, 39]. In add splicing [32, 36, 37] Despite these challenges, eQTL have successfully been used to identify causa<br>genes.[38, 39]. In addition, recent prioritization approaches such as the Locus to Gene (L2G) score<br>Open Targets have shown enes.[38, 39]. In addition, recent prioritization approaches such as the Locus to Gene (L2G) scores<br>
Open Targets have shown that incorporating molecular trait information does increase performane<br>
identify relevant genes. 64 Open Targets have shown that incorporating molecular trait information does increase performance to<br>65 identify relevant genes.[26]<br>66 Here, we sought to use currently available eQTL information to identify disease rele

65 Identify relevant genes. [26]<br>66 Here, we sought to use currently available eQTL information to identify disease relevant genes in the<br>67 context of drug discovery. We first derived a simple approach to prioritize causa Fig. 3. There, we sought to use curre<br>67 identicate for drug discovery. We<br>68 Identify relation MR[40], eQTL colocalization 67 context of drug discovery. We first derived a simple approach to prioritize causal genes based on<br>MR[40], eQTL colocalization[31], activity-by-contact (ABC) enhancer-promoter interactions [41], and<br>MR[40], eQTL colocali 68 MR[40], eQTL colocalization[31], activity-by-contact (ABC) enhancer-promoter interactions[41], a<br>MR[40], eQTL colocalization[31], activity-by-contact (ABC) enhancer-promoter interactions[41], a  $\mathcal{A} = \mathcal{B} + \mathcal{B} + \mathcal{B}$ 

4

\<br>E<br>k For the main annualization procedure is a warrent information about directionality. We show that this approach<br>erriches for gold standard genes[26] and captures known target biology. In addition, genes priorition<br>by this a 20 enriches for gold standard genes[26] and captures known target biology. In addition, genes prioritized<br>21 by this approach are enriched for drug targets with successful clinical trials, and directionality inferred<br>21 by 22 by this approach are enriched for drug targets with successful clinical trials, and directionality inferred<br>23 by MR or coding variants recapitulate drug mechanisms of action (MoA). Finally, we show that this<br>24 approac by MR or coding variants recapitulate drug mechanisms of action (MoA). Finally, we show that this<br>approach can be used to identify drug indication expansion opportunities using genes related to the ILI<br>R as a case study an 23 by Mapproach can be used to identify drug indication expansion opportunities using genes related to the<br>The R as a case study and identify a novel association between *IL6ST* and polymyalgia rheumatica.<br>The METHODS 24 approach can be used to identify a novel association between *IL6ST* and polymyalgia rheumatica.<br>
75 R as a case study and identify a novel association between *IL6ST* and polymyalgia rheumatica.<br>
77 **METHODS** 75 R as a case study and identify a novel association between IL6ST and polymyalgia rheumatica.<br>76<br>78 Estonian Biobank GWAS

--<br>77<br>78<br>79<br>80 78 <u>Estonian Bi</u><br>79 The Estonia<br>80 freeze was<br>81 consent for The Estonian Biobank (Es<br>
80 Freeze was used for the a<br>
81 Consent form<br>
82 All EstBB participants have 79 The Estonian Biobana Richt (Estonian Biobank (Estonian Biobank participants have signed a broad infor<br>1996 The Estonian Biobank (Estonian Biobank participants have signed a broad infor<br>1998 All EstBB participants have b 81 freeze was used for the analyses described here. All biological and support formed the analyses described here.<br>82 All EstBB participants have been genotyped at the Core Genotyping Lab of the Institute of Genomics,<br>83 U

82 All EstBB partion<br>83 University of T<br>84 PLINK format form.<br>85 analysis if their

83 University of Tartu, using Illumina Global Screening Array v1.0 and v2.0. Samples were genotyped and<br>84 PLINK format files were created using Illumina GenomeStudio v2.0.4. Individuals were excluded from<br>85 analysis if t

84 PLINK format files were created using Illumina GenomeStudio v2.0.4. Individuals were excluded from t<br>85 analysis if their call-rate was <95% or if sex defined based on heterozygosity of X chromosome did not<br>86 match sex

match sex in phenotype data. Before phasing and imputation, variants were filtered by call-rate <95%,<br>87 HWE p value $\sqrt{2}$  and all variants only), and minor allele frequency <1%. Variant positions wer<br>88 updated to b37 an

analysis if their call-rate was <95% or if sex defined based on heterozygosity of X chromosome did not<br>match sex in phenotype data. Before phasing and imputation, variants were filtered by call-rate <95%,<br>HWE p value all HWE p value and phenotype data. Before phasing and imputation, variant in the interest of phasing series in phenomenon, and the properties and positions were updated to b37 and all variants were changed to be from TOP stra

updated to b37 and all variants were changed to be from TOP strand using GSAMD-24v1-<br>89 0\_20011747\_A1-b37.strand.RefAlt.zip files from https://www.well.ox.ac.uk/~wrayner/strand/ webpage<br>81 Eagle uses when phasing each samp 89 0\_20011747\_A1-b37.strand.RefAlt.zip files from https://www.well.ox.ac.uk/~wrayner/str<br>80 Chip data pre-phasing was done using Eagle v2.3 software [43] (number of conditioning h<br>81 Eagle uses when phasing each sample was

89 Chip data pre-phasing was done using Eagle v2.3 software [43] (number of conditioning haplotypes<br>89 Eagle uses when phasing each sample was set to:-Kpbwt=20000) and imputation was done using Beagle.<br>89 Eagle uses when p 91 Eagle uses when phasing each sample was set to:-Kpbwt=20000) and imputation was done using Be 91 Eagle uses when phasing each sample was set to:–Kpbwt=20000) and imputation was done using Beagle

\<br>|<br><u>|</u>

- 
- 

93 reference panel of 2297 WGS samples was used.[44]<br>94 <u>FinnGen</u><br>95 The FinnGen study (https://www.finngen.fi/en) was described previously.[7] The study is a public<br>96 private research project that combines genetic and he 94 FinnGen<br>95 The FinnGen study (https://www.finngen.fi/en) was o<br>96 private research project that combines genetic and h<br>97 of the EinnGen study is to identify novel medical and 95 The Finn<br>96 private re<br>97 of the Fir<br>98 pre-comp

96 private research projects of the FinnGen study is to identify novel medical and therapeutical insight into human diseases. It is a<br>96 pre-competitive partnership of Finnish biobanks, universities and university hospital

pre-competitive partnership of Finnish biobanks, universities and university hospitals, international<br>pharmaceutical industry partners, and Finnish biobank cooperative (FINBB). A full list of FinnGen<br>partners is published pharmaceutical industry partners, and Finnish biobank cooperative (FINBB). A full list of FinnGen<br>
partners is published here: https://www.finngen.fi/en/partners.<br>
Disease GWAS processing<br>
We retrieved GWAS results from Fi

99 partners is published here: https://www.finngen.fi/en/partners.<br>
99 partners is published here: https://www.finngen.fi/en/partners.<br>
99 Disease GWAS processing<br>
99 We retrieved GWAS results from FinnGen release 10 (R10) 101 Disease GWAS processing<br>102 We retrieved GWAS results from FinnGen release 10 (R10), UK Bi<br>103 meta-analyses between FinnGen, UK Biobank, and Estonian biob<br>104 GWAS to refer to both single study GWAS and meta-analyses

102 We retrieved GWAS result<br>103 meta-analyses between Fi<br>104 GWAS to refer to both sing<br>105 included 4,611 GWAS with 103 meta-analyses between FinnGen, UK Biobank, and Estonian biobank. For simplicity, we use the term<br>104 GWAS to refer to both single study GWAS and meta-analyses throughout the manuscript. In total, we<br>105 included 4,611 104 GWAS to refer to both single study GWAS and meta-analyses throughout the manuscript. In total, we<br>105 included 4,611 GWAS with at least one variant with  $P<1x10^6$ . When appropriate, we lifted over varia<br>106 from hg38

105 included 4,611 GWAS with at least one variant with  $P<1x10^{-6}$ . When appropriate, we lifted over varian<br>106 from hg38 to hg19 using the liftOver R package[46]. Variant with a minor allele frequency (MAF) <<br>107 0.0001

included 4,611 GWAS with at least one variant with P<1x10<sup>-</sup>. When appropriate, we lifted over variants<br>from hg38 to hg19 using the liftOver R package[46]. Variant with a minor allele frequency (MAF) <<br>0.0001 were exclude 107 0.0001 were excluded from the analysis. For each GWAS, we considered genes located within 250k<br>108 variant with  $P<1x10^{-6}$  for further analysis. For gold standard and clinical trial enrichment analyses<br>109 (describe

- 
- 108 variant with P<1x10<sup>-6</sup> for further analysis. For gold standard and clinical trial enrichment analyses<br>109 (described below), only genome-wide significant loci were included (P<5x10<sup>-8</sup>). We excluded the human<br>110 leuk variant with P<1x10<sup>-6</sup> for further analysis. For gold standard and clinical trial enrichment analyses<br>
(described below), only genome-wide significant loci were included (P<5x10<sup>-8</sup>). We excluded the h<br>
leukocyte antigen
- 

(described below), only genome-wide significant loci were included (P<5x10 °). We excluded the human<br>110 leukocyte antigen (HLA) region in all analyses.<br>111 Disease EFO mapping<br>112 In order to perform semantic integration 111 Disease EFO mapping<br>112 In order to perform semantic integration of ge<br>113 Experimental Factor Ontology (EFO) was used. 112 In order to perform se<br>113 Experimental Factor O 113 Experimental Factor Ontology (EFO) was used. We used the EFO to map traits to their corresponding<br>113 Experimental Factor Ontology (EFO) was used. We used the EFO to map traits to their corresponding  $113$  Experimental Factor  $\mathsf{O}(\mathsf{C}^2)$  was used. We used the EFO to map traits to the EFO to  $\mathsf{O}(\mathsf{C}^2)$ 



120 predicted gain or loss of function (GoLoF) variants from LoGoFunc[47], and linked non-coding variants is<br>121 genes using activity-by-contact (ABC) maps[41]. ABC scores represent the contribution of an enhancer<br>122 the

121 genes using activity-by-contact (ABC) maps[41]. ABC scores represent the contribution of an enhancer to<br>122 the regulation of gene, measured by multiplying the estimates of enhancer activity and three-<br>123 dimensional

122 the regulation of gene, measured by multiplying the estimates of enhancer activity and three-<br>123 dimensional contact frequencies between enhancers and promoters. ABC max refers to variant-gene<br>124 pairs with the highe

pairs with the highest ABC score. We also retrieved disease mutations from the Human Gene Mutation<br>125 Database (HGMD) (license acquired via Qiagen, Maryland)[48]<br>126 Mendelian randomization & colocalization<br>127 We perform

# 126 Mendelian randomization & colocalization

24 Pairs with the highest ABC score. We also retrieve also retrieved in the Human Gene Mutation.<br>125 Database (HGMD) (license acquired via Qiagen, Maryland)[48]<br>127 We performed transcriptome wide MR using the R package Tw Mendelian randomization & colocalization<br>127 We performed transcriptome wide MR using the R package Tw<br>128 Instrument was present, we used the inverse variant weighted<br>129 Ratio annoach, We considered the following exposur 127 We performed transcriptome wide MR usint<br>128 Instrument was present, we used the inverse<br>129 Ratio approach. We considered the followint<br>130 Let al [49], and expression quantitative trait Internal transcribed approach, otherwise we used the Wald<br>129 Instrument was present, we used the following exposures: protein quantitative trait loci (pQTL) from Sun<br>130 Internal Equipment of the FalleMR expression quanti Ratio approach. We considered the following exposures: protein quantitative trait loci (pQTL) from Sun<br>2130 et al [49], and expression quantitative trait loci from Blueprint[50], eQTLGen [51] and other datasets<br>2131 from t 130 et al [49], and expression quantitative trait loci from Blueprint[50], eQTLGen [51] and other datasets<br>131 from the EBI eQTL catalogue[51-75]. In total, 110 molQTL from 26 studies were included. For each of<br>132 those s 131 from the EBI eQTL catalogue [51-75]. In total, 110 molQTL from 26 studies were included. For each of<br>132 those studies, we excluded variants with a MAF < 1%. We clumped variants using PLINK [76] using the<br>133 options – 132 those studies, we excluded variants with a MAF < 1%. We clumped variants using PLINK[76] using the<br>133 options –clump-p1 1 –clump-p2 1 –clump-r2 0.01 – clump-kb 10000 and using the European ancestry<br>134 subset of the options –clump-p1 1 –clump-p2 1 –clump-r2 0.01 – clump-kb 10000 and using the European ancestry<br>subset of the 1000 Genomes Project phase 3 data as reference[77]. We only considered genes 250kb<br>around significant loci in t 134 subset of the 1000 Genomes Project phase 3 data as reference[77]. We only considered genes 250kb<br>135 around significant loci in this analysis. For each QTL, independent variants with  $P<1x10^4$  were used as<br>136 instru are a subseted and significant loci in this analysis. For each QTL, independent variants with  $P<1x10^4$  were used as<br>instruments. For genes with significant MR results (false discovery rate < 0.05), we also performed<br>in around significant loci in this analysis. For each QTL, independent variants with  $P<1x10^-$  were used as<br>136 instruments. For genes with significant MR results (false discovery rate  $< 0.05$ ), we also performed<br>135 arou  $136$  instruments. For generating significant MR results (factorize), we also performed performance  $\mu$ 

- 
- $\frac{1}{1}$ 138 Harmonization between the QTL and GWAS datasets was performed using the harmonise\_data funct<br>139 in the TwoSampleMR package[40]. Only autosomes were included in this analysis.<br>140 <u>Causal gene prioritization</u><br>141 We pr
- 
- 
- in the TwoSampleMR package[40]. Only autosomes were included in this analysis.<br>
140 Causal gene prioritization<br>
141 We prioritized genes as putatively causal using a combination of evidence including MR, colocalization<br>
14
- 149 Causal gene prioritization<br>149 Causal gene prioritization<br>142 H4 posterior probabilities (PP) with molQTL, presence of an associated GoLoF varia<br>143 Coding variants distance to lead variant, and enhancer-promoter ARC s 141 We prioritized genes as pu<br>
142 H4 posterior probabilities<br>
143 coding variants, distance t<br>
144 genes as follow:
- 
- 





- 
- 165 GWAS of the same disease). We then compared this ratio to the fraction of prioritized indications via<br>166 colocalization of the same eQTL dataset over all prioritized indications genome wide. In other words, we<br>9 166 colocalization of the same eQTL dataset over all prioritized indications genome wide. In other words,  $\frac{1}{2}$ 166 colocalization of the same eQTL dataset over all prioritized indications genome wide. In other words, we

ة<br>ما<br>ا

168 associated indications compared to the genome-wide distribution. This corresponds to the follo<br>
169 contingency table:<br>  $\sum_i C_{ijK}$   $\sum_i \sum_{k \neq K} C_{ijk}$ <br>  $\sum_i \sum_{k \neq K} C_{ijk}$ <br>  $\sum_i \sum_{k \neq K} C_{ijk}$ 

$$
\sum_i C_{ijk} \qquad \sum_i \sum_{k \neq K} C_{ijk}
$$

169 contingency table:  
\n
$$
\sum_{i} C_{ijK} \qquad \sum_{i} \sum_{k \neq K} C_{ijk}
$$
\n171  
\n
$$
\sum_{i} \sum_{j \neq J} C_{ijK} \qquad \sum_{i} \sum_{k \neq K} \sum_{j \neq J} C_{ijk}
$$

170<br>171<br>172 Where  $C_{ijk}$ =1 if dise 170  $\sum_i \sum_j e_i$ <br>171  $\sum_i \sum_{j \neq j}$ <br>172 Where  $C_{ijk}$ =1 if disease *i* colocalize with price<br>173 were calculated using Fisher exact tests. Fa<br>174 considered significant  $\sum_{i} \sum_{k \neq K} C_i$ <br>  $\sum_{i} \sum_{k \neq K} \sum_{j \neq K}$ <br>  $\sum_{i} \sum_{k \neq K} \sum_{j \neq K} C_i$ <br>  $\sum_{i} \sum_{k \neq K} C_i$ <br>  $\sum_{i} \sum_{k \neq K} C_i$ 171  $\Delta i \Delta j \neq J$ <br>
172 Where  $C_{ijk}$ =1 if disease *i* colocalize with pric<br>
173 were calculated using Fisher exact tests. Fa<br>
174 considered significant.<br>
175 Forichment of disease categories for single  $i j K$   $\Delta i \Delta k \neq K \Delta j \neq J$ <br>tized gene  $j$  in tissue<br>e discovery rate (FDF<br>enes  $an$ <br>and 172 Where Ci<sub>jk</sub>e-1 in disease i colocalize with prioritized gene j in tissue k and 0 if not. P-values and odds ratios<br>173 were calculated using Fisher exact tests. False discovery rate (FDR) adjusted *P*-values < 0.05 we were calculated using Fisher exact tests. False discovery rate (FDR) adjusted P-values < 0.05 were<br>considered significant.<br>173 Enrichment of disease categories for single genes<br>176 To identify enrichment disease categories

# 175 <u>Enrichment of disease</u><br>176 To identify enrichment<br>177 GWAS where the genes<br>178 for that gene We then

177 GWAS where the genes is prioritized for a given EFO category over the total number of prioritized GV<br>178 for that gene. We then compared this ratio to the genome-wide ratio of GWAS for this EFO category<br>179 over the t

178 for that gene. We then compared this ratio to the genome-wide ratio of GWAS for this EFO category<br>
179 over the total number of tested GWAS. This corresponds to the following contingency table:<br>  $\sum_i D_{ijc}$   $\sum_i \sum_{c \neq$ 

176 To identify enrichment disease categories for sing<br>177 GWAS where the genes is prioritized for a given El<br>178 for that gene. We then compared this ratio to the<br>179 over the total number of tested GWAS. This corres 179 over the total number of tested GWAS. This corresponds to the following contingency table:<br>
180  $\Sigma_i D_{ijc}$   $\Sigma_i \Sigma_{c \neq c} D_{ijc}$ <br>
181  $\Sigma_i \Sigma_{j \neq j} D_{ijc}$   $\Sigma_i \Sigma_{c \neq c} \Sigma_{j \neq j} D_{ijc}$ 

- $\sum_i D_{ijc}$   $\sum_i \sum_{c \neq c} D_{ijc}$
- $\Delta$ i $\Delta$ j≠J $\Delta$ ij $\epsilon$   $\Delta$ i $\Delta$ c≠C $\Delta$ j≠J $\Delta$ ijc

180  $\sum_i D_{ijC}$   $\sum_i \sum_{c \neq C} D_{ijC}$ <br>181  $\sum_i \sum_{j \neq J} D_{ijC}$   $\sum_i \sum_{c \neq C} \sum_{j \neq J} D_{ijc}$ <br>182 Where  $D_{ijk}$ =1 if disease *i* is prioritized for gene *j* and belongs to category *c* and 0 if not. *P*-value 180  $\sum_i D_{ij}$ <br>
181  $\sum_i \sum_{j \neq j} I$ <br>
182 Where  $D_{ijk}$ =1 if disease *i* is prioritized for gen<br>
183 ratios were calculated using Fisher exact test<br>
184 significant  $\sum_{i} \sum_{c \neq c} \sum_{j \neq j}$ <br>  $D_{ijc}$   $\sum_{i} \sum_{c \neq c} \sum_{j \neq j}$ <br>  $E_j$  and belongs to cat<br>  $E_S$ . FDR adjusted *P*-va  $j D_{ij}c$   $\qquad \angle i \angle c \neq c \angle j \neq j$ <br>ene *j* and belongs to ca<br>ests. FDR adjusted *P*-va<br>thment ---<br>182<br>183<br>184<br>185 182 Where  $D_{ijk}=1$  if disease is promized for gene j and belongs to category c and 0 if not. P-values and odds<br>
183 ratios were calculated using Fisher exact tests. FDR adjusted P-values < 0.05 were considered<br>
184 Signifi 184 significant.<br>184 significant.<br>185 Disease colocalizing molQTL cell-type enrichment

# 185 Disease colu 185 Disease colocalizing molQTL cell-type enrichment

 $\frac{1}{2}$ 187 al. 2021.[79] Briefly, we extracted all GWAS colocalizing molQTL (H4 probability > 0.8). Then, for a given<br>
188 cell type K and disease category I, we generated the following contingency table:<br>  $\sum_j C_{IjK}$   $\sum_j \sum_{k \ne$ 188 cell type *K* and disease category *I*, we generated the following contingency table:<br>
189  $\sum_j C_{IjK}$   $\sum_j \sum_{k \neq K} C_{Ijk}$ <br>
190  $\sum_j \sum_{i \neq I} C_{ijK}$   $\sum_j \sum_{k \neq K} \sum_{i \neq I} C_{ijk}$ 

189 
$$
\sum_{j} C_{IjK} \qquad \sum_{j} \sum_{k \neq K} C_{Ijk}
$$

189  $\sum_j C_{IjK}$   $\sum_j \sum_{k \neq K} C_{Ijk}$ <br>189  $\sum_j \sum_{i \neq I} c_{ijk}$   $\sum_j \sum_{k \neq K} \sum_{i \neq I} c_{ijk}$ <br>190  $\sum_j \sum_{i \neq I} c_{ijk}$   $\sum_j \sum_{k \neq K} \sum_{i \neq I} c_{ijk}$ <br>191 Where  $C_{ijk}$ =1 if at least one disease GWAS of category *i* colocalize with ge 189<br>
190  $\sum_j \sum_{i \neq j}$ <br>
191 Where  $C_{ijk}$ =1 if at least one disease GWAS<br>
192 values and odds ratios were calculated usi<br>
193 all molOTL separately, as well as by group  $\sum_j \sum_{i \neq I} C_{ijk}$   $\sum_j \sum_{k \neq K} \sum_{i \neq I} C_{ijk}$ <br>Where  $C_{ijk}$ =1 if at least one disease GWAS of category *i* colocalize with gene *j* in tissue *k* and 0 if not. *P*-<br>values and odds ratios were calculated using Fisher exac 190  $\Delta j \Delta i \neq I$ <br>191 Where  $C_{ijk}$ =1 if at least one disease GWAS of<br>192 values and odds ratios were calculated using<br>193 all molQTL separately, as well as by grouping<br>194 enrichment. FDR adjusted *P*-values < 0.05 we  $i j K$   $\Delta j \Delta k \neq K \Delta i \neq I$ <br>
category *i* colocalize w<br>
Fisher exact tests. We<br>
similar cell types and<br>
ere considered significa  $x$ <br> $y \kappa$ 191 Where  $C_{ijk}=1$  if at least one disease GWAS of category i colocalize with gene j in tissue k and 0 if not. P-<br>192 values and odds ratios were calculated using Fisher exact tests. We performed the analysis considerin<br>19 all molQTL separately, as well as by grouping similar cell types and tissues together prior to testing for<br>194 enrichment. FDR adjusted P-values < 0.05 were considered significant.<br>195 Drug target-indication pairs in clini

193 all mold separately, as well as by grouping similar cell types and include types upon prior to testing for<br>193 all mold increases to the main similar prior to testing in the prior together prior to testing to the most<br> 194 enrichment. FDR adjusted P-values < 0.05 were considered significant.<br>
195 Drug target-indication pairs in clinical trials<br>
196 Information about drugs approved or in clinical trials was obtained from<br>
197 Pharma Intel 196 Information about drugs approved or in clin<br>197 Pharma Intelligence, which is a superset of t<br>198 streams, including nightly feeds from officia<br>199 data from primary sources such as institutio 197 Pharma Intelligence, which is a superset of the most used data sources. In addition to multiple data<br>198 streams, including nightly feeds from official sources such as ClinicalTrials gov, Citeline also contains<br>199 dat 198 streams, including nightly feeds from official sources such as ClinicalTrials.gov, Citeline also contains<br>199 data from primary sources such as institutional press releases, financial reports, study reports, and d<br>199 198 data from primary sources such as institutional press releases, financial reports, study reports, and d<br>198 data from primary sources such as institutional press releases, financial reports, study reports, and d<br>198 ma marketing label applications, and secondary sources such as analyst reports by consulting companies.<br>1991 Secondary sources are particularly important to reduce potential biases to the organizations' tenancy to<br>1992 Teport 201 Secondary sources are particularly important to reduce potential biases to the organizations' tenancy<br>202 report only successful trials, especially those before the FDA Amendments Act of 2007, which requires<br>203 all cl 202 report only successful trials, especially those before the FDA Amendments Act of 2007, which requires<br>203 all clinical trials to be registered and tracked by ClinicalTrials gov. Citeline database contains information<br>2 203 all clinical trials to be registered and tracked by ClinicalTrials.gov. Citeline database contains information<br>204 from both US and non-US sources. Any cancer or cancer related indications were excluded from this<br>205 a 204 all clinical transferred and tracked and tracked process and trials to be registered and trial trials.<br>205 analysis.<br>206 In order to map gene-disease pairs in the genetic data to target-indication pairs in the drug dat

205 analysis.<br>206 In order to map gene-disease pairs in the genetic data to target-indication pairs in the drug data, we<br>207 used experimental factor ontology (EFO), which provided a systematic description of many data 206 In order to the same of the same o<br>207 used exp 207 In order to map gene-disease pairs in the generic data to target-indication pairs in the drug data, i.e.<br>207 In used experimental factor ontology (EFO), which provided a systematic description of many data  $207 \times 10^{17}$  used experimental factor ontology (EFO), which provided a systematic description of many data syst

11

ة }<br>}<br>} 209 genetic evidence of association between the gene and disease sufficiently similar to the indication,<br>210 based on semantic similarity. Two methods were used to calculate semantic similarity matrix.[80, 81]<br>211 Semantic 210 based on semantic similarity. Two methods were used to calculate semantic similarity matrix.[80, 8<br>211 Semantic similarities between each pair of EFO headings were computed in the ontologySimilarity F<br>212 package.[82] 211 Semantic similarities between each pair of EFO headings were computed in the ontologySimilarity R<br>212 package. [82] The average of the two methods was calculated and standardized similarities had a<br>213 maximum value of 212 package. [82] The average of the two methods was calculated and standardized similarities had a<br>213 maximum value of 1 for each disease or indication. Two diseases are considered similar if the similar<br>214 is greater t maximum value of 1 for each disease or indication. Two diseases are considered similar if the sim<br>214 is greater than or equal to a previously published value of 0.7.[11]<br>215 Prediction of drug mechanism of action directio 214 is greater than or equal to a previously published value of 0.7.[11]<br>215 Prediction of drug mechanism of action directionality<br>216 We retrieved information about drug mechanism of action from the Informa Pharma Intelli Prediction of drug mechanism of action directionality<br>215 We retrieved information about drug mechanism of action from th<br>217 dataset described above. For targets for which *decreased* expression<br>218 beneficial we consider 216 We retrieved information about drug mechanism of action dataset described above. For targets for which decreantlenality beneficial, we considered datasets with the following "degrader". For targets for which *increased* 217 dataset described above. For targets for which *decreased* expression or loss of function (LoF) is<br>218 beneficial, we considered datasets with the following keywords: "antagonist", "inhibitor", and<br>219 "degrader". For dataset described above. For targets for which decreased expression or loss of function (LoF) is<br>218 beneficial, we considered datasets with the following keywords: "antagonist", "inhibitor", and<br>219 degrader". For targets 219 "degrader". For targets for which *increased* expression or function is beneficial, we considered<br>220 following keyworks: "agonist", and "activator". We considered drugs and targets in phase II clim<br>221 or above. We pe 220 following keyworks: "agonist", and "activator". We considered drugs and targets in phase II clinical<br>221 or above. We performed two analyses to infer directionality from GWAS. First, we assess directiona<br>222 using the 221 or above. We performed two analyses to infer directionality from GWAS. First, we assess directionality<br>222 using the effect size of low-frequency lead coding variant (MAF < 5%). We assumed that these variants<br>223 are d 222 using the effect size of low-frequency lead coding variant (MAF < 5%). We assumed that these variants<br>223 are disruptive or LoF. Therefore, a LoF coding variant associated with increased risk suggests that a drup<br>224 are disruptive or LoF. Therefore, a LoF coding variant associated with increased risk suggests that a drug<br>224 MoA of agonist or activator would be beneficial, whereas for a protective LoF coding variant, an<br>325 inhibitor 224 MoA of agonist or activator would be beneficial, whereas for a protective LoF coding variant, an<br>225 inhibitor or antagonist would be beneficial. Next, we assessed directionality based on the direction of<br>226 effect of

225 inhibitor or antagonist would be beneficial. Next, we assessed directionality based on the directi<br>226 effect of gene expression on disease risk predicted by MR using molQTL as exposure (q-value < 0<br>227 We included onl

226 effect of gene expression on disease risk predicted by MR using molQTL as exposure (q-value < 0.05).<br>227 We included only molQTL colocalizing with local GWAS signal (H4 PP > 80%). For gene-disease pairs<br>228 supported b 227 We included only molQTL colocalizing with local GWAS signal (H4 PP > 80%). For gene-disease pairs<br>228 supported by multiple colocalizing molQTL, a consensus direction was inferred if the MR direction of<br>229 effect was supported by multiple colocalizing molQTL, a consensus direction was inferred if the MR direction or<br>229 effect was consistent across > 75% of the molQTL. Here, a negative consensus MR direction suggests<br>230 that increased 229 effect was consistent across > 75% of the molQTL. Here, a negative consensus MR direction suggests<br>230 that increased gene expression leads to decreased disease risk. Therefore, an activator or agonist dru<br>231 targetin 220 that increased gene expression leads to decreased disease risk. Therefore, an activator or agonist dru<br>231 targeting this gene would be beneficial. Conversely, a positive consensus MR direction suggests that<br>231 target

231 that increased gene expression leads to decrease when therefore, and therefore, and therefore, and therefore, a<br>231 targeting this gene would be beneficial. Conversely, a positive consensus MR direction suggests that 231 targeting this gene would be beneficial. Conversely, a positive consensus MR direction suggests that



244 *Prioritizat*<br>244 *Prioritizat*<br>245 Weaimed<br>246 (UKB)[45] 244 Prioritization of putative causar genes in thousands of GWAS<br>245 We aimed to prioritize causal genes across 4,611 GWAS from<br>246 (UKB)[45], FinnGen release 10 (R10), and meta-analyses of UI<br>247 biobank.[6] For simplicit 246 (UKB)[45], FinnGen release 10 (R10), and meta-analyses of UK Biobank, FinnGen R10, and Estonian<br>247 biobank. [6] For simplicity, we refer to both single studies and meta-analyses as GWAS throughout the<br>248 manuscript. 247 biobank. [6] For simplicity, we refer to both single studies and meta-analyses as GWAS throughout<br>248 manuscript. While molecular QTLs (molQTL) such as expression quantitative trait loci (eQTL) have b<br>249 used previous 248 manuscript. While molecular QTLs (molQTL) such as expression quantitative trait loci (eQTL) have been<br>249 used previously to prioritize causal genes, they are often pleiotropic with the same variant associated<br>250 with 249 used previously to prioritize causal genes, they are often pleiotropic with the same variant associated<br>250 with multiple genes within the same locus.[26, 32, 33] Additional genomic information such as the ABC<br>251 mode with multiple genes within the same locus.[26, 32, 33] Additional genomic information such as the AB<br>251 model have been shown to increase performance to identify causal genes, in particular when selecting<br>252 genes with t 251 with multiple genes with the same location is the same of dentify causal genes, in particular when selecting<br>252 genes with the highest ABC score (ABCmax).[41] Therefore, we derived a ranking scheme to prioritize<br>253 g genes with the highest ABC score (ABCmax).[41] Therefore, we derived a ranking scheme to prioritize<br>253 genes using different features including ABC, molQTL, presence of an associated coding or gain or loss of<br>253 genes us genes using different features including ABC, molQTL, presence of an associated coding or gain or loss<br>genes using different features including ABC, molQTL, presence of an associated coding or gain or loss 253 genes using different features including ABC, molQTL, presence of an associated coding or gain or loss of

f<br>c<br>s 255 datasets from 26 studies using MR to infer causality and directionality of gene expression on disease<br>256 risk. We also performed colocalization analysis to confirm that both GWAS or meta-analyses and molQTL<br>257 signal 256 risk. We also performed colocalization analysis to confirm that both GWAS or meta-analyses and mol<br>257 signals shared at least one causal variant. Top ranking genes were selected as those that either<br>258 contained an a 257 signals shared at least one causal variant. Top ranking genes were selected as those that either<br>258 contained an associated lead coding variant or were supported by both ABCmax and colocalization<br>259 across >2 cell ty 258 contained an associated lead coding variant or were supported by both ABCmax and colocalizat<br>259 across >2 cell types or tissues. We did not include distance to lead variant for higher ranks beca<br>260 wanted to first pr 259 across >2 cell types or tissues. We did not include distance to lead variant for higher ranks because<br>260 wanted to first prioritize genes for which we could identify potential biological mechanisms. Howev<br>261 for loci 260 wanted to first prioritize genes for which we could identify potential biological mechanisms. However,<br>261 for loci without such evidence, or in cases where multiple genes showed identical ranks, the nearest<br>262 gene t 261 for loci without such evidence, or in cases where multiple genes showed identical ranks, the nearest<br>262 gene to the lead variant was selected as the putative causal gene if it was among the best candidates.<br>263 Overal 262 gene to the lead variant was selected as the putative causal gene if it was among the best candidates<br>263 Overall, between 1.1 and 1.4 genes were prioritized per locus (before breaking ties with the nearest<br>264 gene), 263 Overall, between 1.1 and 1.4 genes were prioritized per locus (before breaking ties with the nearest<br>264 gene), with 17-49% of loci supported by molQTL colocalization or coding variants (**Table 1**).<br>265 Enrichment of g

264 gene), with 17-49% of loci supported by molQTL colocalization or coding variants (**Table 1**).<br>265 *Enrichment of genomic features for gold standard genes*<br>266 Comparing the enrichment of different genomic features alon 265 Enrichment of genomic features for gold standard genes<br>266 Comparing the enrichment of different genomic features alone for curated gold standard ge<br>267 found a strong enrichment for genes supported by ABCmax with lead 265 EMEEMENT of genomic features for gold standard genes<br>266 Comparing the enrichment of different genomic features<br>268 P=0.0002-4x10<sup>-6</sup>) (Additional file 1: Figure S1; Additional<br>269 enriched for gold standard genes (col 267 found a strong enrichment for genes supported by ABCmax with lead variant (Odds ratio (OR)=8.0-18.7,<br>268 P=0.0002-4x10<sup>-6</sup>) (Additional file 1: Figure S1; Additional file 2: Table S1). molQTL colocalization also<br>269 en 268  $P=0.0002-4x10^{-6}$  (Additional file 1: Figure S1; Additional file 2: Table S1). molQTL colocalization also<br>269 enriched for gold standard genes (colocalization H4 posterior probability (PP) > 95%, OR=3.4-17.7,<br>270  $P=$ 268  $P=0.0002-4x10^{-9}$  (Additional file 1: Figure S1; Additional file 2: Table S1). molQTL colocalization also<br>
269 enriched for gold standard genes (colocalization H4 posterior probability (PP) > 95%, OR=3.4-17.7,<br>
270 270  $P=0.001-2x10^{-12}$ ). However, the strongest enrichment was generally observed for genes with associalized coding variants[47] (OR>36.2,  $P=0.0002-2x10^{-10}$ ) and the nearest gene (OR=17.7-38.7,  $P=3x10^{-12}$ ). The stron  $P=0.001-2x10^{-2}$ ). However, the strongest enrichment was generally observed for genes with associated<br>
lead coding variants[47] (OR>36.2,  $P=0.0002-2x10^{-10}$ ) and the nearest gene (OR=17.7-38.7,  $P=3x10^{-9}$ -<br>
1x10<sup>-25</sup>). lead coding variants[47] (OR>36.2, P=0.0002-2x10<sup>-v</sup>) and the nearest gene (OR=17.7-38.7, P=3x10<sup>-2</sup><br>
1x10<sup>-25</sup>). The strong enrichment for nearest genes is expected given that the gene closest to the lead<br>
1x10<sup>-25</sup>). Th 1x10<sup>-2</sup>). The strong enrichment for nearest genes is expected given that the gene closest to the lead<br>173 variant is often the causal gene. In addition, several of the gold standard genes have been selected<br>174 because t because they are supported by coding variants or tend to fall in the center of GWAS peaks and have<br>275 been investigated more closely[26]. However, when using these features in combination, we found<br>276 our ranking approac been investigated more closely[26]. However, when using these features in combination, we found to our ranking approach performed well and generally better than selecting the nearest gene alone, with our ranking approach p 276 between investigated more closely  $\frac{1}{2}$ . The contract of the selecting the nearest gene alone, with a contracting approach performed well and generally better than selecting the nearest gene alone, with a selectin  $2.76$  our ranking approach performed well and generally better than selecting the nearegies alone, with a<br> $14$ 

- r<br>S 278 S1).<br>279 Gain and Loss of function variants identify genes linked to monogenic disorders<br>280 Integrating information about GoLoF variants retrieved variants linked to monogenic disorders including<br>281 PSEN1 with Alzhei
- 
- ,<br>279 *Gain*<br>280 Inte<sub>l</sub><br>281 *PSEI*<br>282 diser 280 Integrating information about GoLoF variants retrieved variants linked to monogenic disorders including<br>
281 PSEN1 with Alzheimer's disease (AD)[85] (rs764971634, p.Ile437Val, P=2x10<sup>-12</sup>), SQSTM1 and Paget's<br>
282 dis
- 
- 
- 279 Gain and Eoss of function variants factingly genes linked to monogenic disorders<br>280 Integrating information about GoLoF variants retrieved variants linked to mono<br>281 *PSEN1* with Alzheimer's disease (AD)[85] (rs7649
- 281 *PSEN1* with Alzheimer's disease (AD)[85] (rs764971634, p.Ile437Val,  $P=2x10^{-2}$ ), SQSTM1 and Paget's<br>
disease[86] (rs104893941, p.Pro392Leu,  $P=6x10^{-11}$ ), and *HFE* and disorders of iron metabolism[87]<br>
(rs1800562, disease[86] (rs104893941, p.Pro392Leu,  $P=6x10^{-11}$ ), and HFE and disorders of iron metabolism[87]<br>
(rs1800562, p.Cys282Tyr,  $P=1x10^{-178}$ ) (Figure 1B; Additional file 2: Table S3). We also identified<br>
protective GoLoF va
- 
- 
- (rs1800562, p.Cys282Tyr, P=1x10<sup>-178</sup>) (Figure 1B; Additional file 2: Table S3). We also identified<br>284 protective GoLoF variants such as *APP* p.Ala673Thr (rs63750847, P=7x10<sup>-11</sup>) reducing odds of de<br>285 AD[88], and *AL* protective GoLoF variants such as *APP* p.Ala673Thr (rs63750847,  $P=7x10^{-1}$ ) reducing odds of developing<br>285 AD[88], and *ALOX15* p.Thr560Met protecting against nasal polyps (rs34210653,  $P=2x10^{-15}$ )[89]. Of 208<br>286 gen AD[88], and *ALOX15* p.1 hr560Met protecting against nasal polyps (rs34210653, *P*=2x10<sup>-15</sup>)[89]. Of 208 genes prioritized with at least one predicted GoLoF variant, 179 had at least one disease mutation reported in the 287 reported in the Human Gene Mutation Database (HGMD)[48] (OR = 2.3 [1.5-3.6], P=5x10<sup>-6</sup>). Potent<br>
288 novel associations included *COLGALT2* and arthrosis (rs35937944, p.Tyr212Cys, P=2x10<sup>-14</sup>), *LRG5* an<br>
289 carcino
- reported in the Human Gene Mutation Database (HGMD)[48] (OR = 2.3 [1.5-3.6],  $P=5x10^{-9}$ ). Potential<br>novel associations included *COLGALT2* and arthrosis (rs35937944, p.Tyr212Cys,  $P=2x10^{-14}$ ), *LRG5* and<br>carcinoid syndr
- novel associations included *COLGALT2* and arthrosis (rs3593/944, p.Tyr212Cys, P=2x10<sup>-++</sup>), *LRG5* and<br>289 carcinoid syndrome (rs200138614, p.Cys712Phe, P=4x10<sup>-9</sup>), and *GREB1* and female infertility<br>290 (rs755857714, p.
- 
- 

carcinoid syndrome (rs200138614, p.Cys712Phe, P=4x10<sup>-</sup>), and *GREB1* and female infertility<br>290 (rs755857714, p.Arg1339His, P=4x10<sup>-9</sup>).<br>291 *Colocalizing molQTL link genes to diseases and pathogenic tissues*<br>292 Prioriti (rs755857714, p.Arg1339His, P=4x10°).<br>291 *Colocalizing molQTL link genes to diseas*<br>292 Prioritized candidate causal genes show<br>293 known function. For instance, colocalizir<br>294 disease categories such as *EDNRA 1PA* a 291 Colocalizing molocy L link genes to diseases and pathogenic tissues<br>292 Prioritized candidate causal genes showed enrichment in disease c<br>293 known function. For instance, colocalizing molQTL for prioritized g<br>294 dis 293 known function. For instance, colocalizing molQTL for prioritized genes supported associations with<br>294 disease categories such as *EDNRA, LPA* and *FGF5* with cardiovascular diseases (*P<*2x10<sup>-16</sup>), *TSLP*, *IL33* a 294 disease categories such as *EDNRA*, *LPA* and *FGF5* with cardiovascular diseases (*P<*2x10<sup>-16</sup>), *TSLP*, *IL33*<br>295 *CHRNA3* and respiratory system diseases (*P<*7x10<sup>-21</sup>), and *II23R*, *TYK2*, *IL10* and immune sy disease categories such as *EDNRA*, *LPA* and *FGF5* with cardiovascular diseases (*P<*2x10<sup>-v</sup>), *TSLP*, *IL33* and<br> *CHRNA3* and respiratory system diseases (*P<*7x10<sup>-21</sup>), and *II23R*, *TYK2*, *IL10* and immune system CHRNA3 and respiratory system diseases (P</x10  $^{22}$ ), and II23R, TYK2, IL10 and immune system disease<br>
(P<5x10<sup>-11</sup>) (Figure 1C-D; Additional file 2: Table S4). In addition, we found an enrichment of disease<br>
colocalizi 296 (P<5x10<sup>-11</sup>) (Figure 1C-D; Additional file 2: Table S4). In addition, we found an enrichment of disease<br>297 colocalizing eQTLs in kidney cortex for *FGF5*, a gene expressed during kidney development and<br>298 associate 298 associated with kidney function  $(P=4x10^{-15})$ [90] (Figure 1E; Additional file 2: Table S5). Other expressed in a metally associated with kidney function  $(P=4x10^{-15})$ [90] (Figure 1E; Additional file 2: Table S5). Other associated with kidney function (P=4x10<sup>-2</sup>)[90] (**Figure 1E; Additional file 2: Table S5**). Other examples<br>include artery eQTLs for the cardiovascular diseases associated gene *PHACTR1*[91] (*P=*1x10<sup>-9</sup>); the<br>1 include artery eQTLs for the cardiovascular diseases associated gene  $PHACTR1[91]$  ( $P=1x10^{-2}$ ); the  $\frac{200}{200}$ 

 $\frac{1}{\epsilon}$ lysosomal acid lipase (LIPA) gene and microglia eQTLs (P=1x10<sup>-v</sup>); and the ABO with plasma pQTL<br>
(P=1x10<sup>-20</sup>). Finally, we confirmed that enriched colocalizing eQTLs matched the expected pathoge<br>
dissues and cell-types  $(2-1 \times 10^{-2})$ . Finally, we confirmed that enriched colocalizing eQTLs matched the expected pathogenic<br>
solong tissues and cell-types of different disease categories (**Figure 1F; Additional file 2: Table S6**). For instan<br> 303 after grouping eQTL of similar tissues and cell types together, we found a strong enrichment of genes<br>304 with artery and heart eQTL colocalizing with cardiovascular disease GWAS ( $P < 9 < x10^{-17}$ ). We found<br>305 similar 304 with artery and heart eQTL colocalizing with cardiovascular disease GWAS ( $P < 9 < x 10^{-17}$ ). We found<br>305 similar enrichment for T cell and thyroid eQTLs in endocrine system diseases ( $P < 3x 10^{-8}$ ); blood,<br>306 lymphob with artery and heart eQTL colocalizing with cardiovascular disease GWAS ( $P<9). We found<br>similar enrichment for T cell and thyroid eQTLs in endocrine system diseases ( $P<3x10^{-8}$ ); blood,<br>lymphoblastoid cell l$ similar enrichment for T cell and thyroid eQTLs in endocrine system diseases (P<3x10<sup>-</sup>); blood,<br>1986 ) hymphoblastoid cell line, monocytes, neutrophil, and T cells with immune system diseases (P<4x430<sup>-6</sup>); and fibroblas lymphoblastoid cell line, monocytes, neutrophil, and I cells with immune system diseases (P<4x10 $^{\circ}$ );<br>and fibroblasts and musculoskeletal diseases (P<4x10 $^{\circ}$ ). Treating each eQTL data separately revealed<br>additional and fibroblasts and musculoskeletal diseases (P<4x10<sup>-</sup>). I reating each eQTL data separately revealed<br>additional associations with tissues or cell subsets including brain cortex and diseases of the visual<br>system (P<6x10<sup></sup> 310 system ( $P<6x10^{-6}$ ); cerebellum and nervous system diseases ( $P<4x10^{-6}$ ); regulatory T cells and endo<br>310 system diseases ( $P<9x10^{-9}$ ); and T helper 17 cells and digestive system diseases ( $P<5x10^{-7}$ ) (Additio system (P<6x10<sup>-</sup>); cerebellum and nervous system diseases (P<4x10<sup>-</sup>); regulatory T cells and endocrine<br>system diseases (P<9x10<sup>-9</sup>); and T helper 17 cells and digestive system diseases (P<5x10<sup>-7</sup>) (**Additional**<br>f**ile 1** system diseases (P<9x10-7); and T helper 17 cells and digestive system diseases (P<5x10-7) (**Additional**<br> **iie 1: Figure 54; Additional file 2: Table 57**). Overall, the analyses illustrate that in contrast to the<br>
nearest means generally shaking in the streaments of the analyses increased into the analyses increased its<br>312 The arest gene approach, inclusion of eQTL can help identify potential pathogenic cell types and tiss<br>313 Prioritized

313 Prioritized genes increase clinical trial probability of success<br>314 Building on these results, we tested whether we could use molQTL information of putative causal gene<br>315 to drive drug repurposing opportunities or i 313 Priorinzed genes increase clinical trial probability of success<br>314 Building on these results, we tested whether we could use n<br>315 to drive drug repurposing opportunities or identify potentia<br>316 whether the prioritiz 315 to drive drug repurposing opportunities or identify potential safety concerns. First, we evaluated<br>316 whether the prioritized genes enriched for therapeutic targets with clinical trial success. Clinical trial<br>317 info 316 whether the prioritized genes enriched for therapeutic targets with clinical trial success. Clinical t<br>317 information was retrieved from the Citeline Pharma Intelligence project. Consistent with previou<br>318 observatio 317 information was retrieved from the Citeline Pharma Intelligence project. Consistent with previous<br>318 observations, we found that targets with clinical trial success were enriched for features such as<br>319 presence of c 318 observations, we found that targets with clinical trial success were enriched for features such as<br>319 presence of coding variation (Figure 2A, Additional file 2: Table S8). For example, gain or loss of<br>320 function le 319 presence of coding variation (**Figure 2A, Additional file 2: Table S8**). For example, gain or loss of<br>320 function lead variants demonstrated some of the best predictive performances, in particular usir<br>321 genetic evi 320 function lead variants demonstrated some of the best predictive performances, in particular usir<br>321 genetic evidence from the UKB EUR ICD10 (Phase I: Risk ratio (RR)=1.23, P=0.104; Phase II: RR=1.<br>322 P=0.0688; Phase sential variants demonstrated some of the best prediction performances, in particular anning<br>321 genetic evidence from the UKB EUR ICD10 (Phase I: Risk ratio (RR)=1.23, P=0.104; Phase II: RR=1.33<br>322 P=0.0688; Phase III: R  $P=0.0688$ ; Phase III: RR=2.08,  $P=0.0023$ ; Approved: RR=2.67,  $P=0.00378$ ). Similar results were observations at a studies. Use of epigenetic evidence also improved predictions, for example, lead SNPs linkert across all  $323$  P=0.0688, Phase III: RR=2.08, P=0.0023; Approved: RR=2.67, P=0.00378). Similar results were observed<br>across all studies. Use of epigenetic evidence also improved predictions, for example, lead SNPs linked<br>1

323 across all studies. Use of epigenetic evidence also improved predictions, for example, lead SNPs linked



339 *Inferred directionality*<br>340 To understand wheth<br>341 the consistency betw<br>342 (methods) When col 3339 Inferred directionality from GWAS recapitative drug incentifisms by detion<br>340 To understand whether inferred directionality could inform on clinical trial<br>341 the consistency between the direction of effect of coding 341 the consistency between the direction of effect of coding variants and drug mechanism of action (MoA)<br>342 (methods). When considering prioritized genes with lead low-frequency coding variants (minor allele<br>343 frequen 342 (methods). When considering prioritized genes with lead low-frequency coding variants (minor allele<br>343 frequency < 0.05) and clinical trials phase II and above, between 83% and 96% of showed consistent<br>344 effect betw 343 frequency < 0.05) and clinical trials phase II and above, between 83% and 96% of showed consistent<br>344 effect between the minor allele and drug MoA (Fisher P=0.08-6x10<sup>8</sup>, **Figure 2C**). We then asked whet<br>345 molQTL co 344 effect between the minor allele and drug MoA (Fisher  $P=0.08-6\times10^{-8}$ , Figure 2C). We then asked whe<br>345 molQTL could similarly inform on directionality. Using prioritized gene-disease pairs supported by MI<br>346 value effect between the minor allele and drug MoA (Fisher P=0.08-6x10<sup>-</sup>, Figure 2C). We then asked whether<br>molQTL could similarly inform on directionality. Using prioritized gene-disease pairs supported by MR (q-<br>value < 0.05) 146 value of 186 values and colocalization (PP 300), we interred the direction of effect was consistent across >75% of molQTL datasets for a given gene. This was the case for most gene<br>347 values of effect was consistent a

# It is made available under a COBBY-IMC-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.11.01.23297926;](https://doi.org/10.1101/2023.11.01.23297926) this version posted November 1, 2023. The copyright holder for this preprint



352 Causal gene predication from GWAS identifies a link between IL6ST and polymyalg<br>353 Finally, we applied our causal gene prioritization approach to a specific use case, t<br>354 potential new indications for drugs targetin 353 Finally, we applied our causal gene prioritization approach to a specific use case, that is identifying<br>354 potential new indications for drugs targeting the IL6 receptor such as Sarilumab and Tocilizumab<br>355 drugs app 354 potential new indications for drugs targeting the IL6 receptor such as Sarilumab and Tocilizumab, b<br>355 drugs approved for rheumatoid arthritis. We extracted diseases prioritized by our approach for gen<br>356 related to 355 drugs approved for rheumatoid arthritis. We extracted diseases prioritized by our approach for genes<br>356 related to the receptor, namely IL6, IL6ST, and IL6R. We identified putative causal links between<br>357 increased I 1356 related to the receptor, namely *IL6, IL6ST*, and *IL6R*. We identified putative causal links between<br>357 increased *IL6* expression in CD16 monocytes and increased risk of varicose veins, ischemic heart diseases<br>358 increased *IL6* expression in CD16 monocytes and increased risk of varicose veins, ischemic heart coronary atherosclerosis, and atrial fibrillation (MR beta > 0), but decreased risk of asthma and al (MR beta < 0) (**Additio** 358 coronary atherosclerosis, and atrial fibrillation (MR beta > 0), but decreased risk of asthma and allergy<br>359 (MR beta < 0) (Additional file 1: Figure S7; Additional file 2: Table S10). eQTL of *IL6* in whole blood als 359 (MR beta < 0) (Additional file 1: Figure S7; Additional file 2: Table S10). eQTL of *IL6* in whole blood also<br>360 supported these disease associations, albeit with an opposite predicted direction of effect. Similarly,<br> supported these disease associations, albeit with an opposite predicted direction of effect. Similarly,<br>361 *IL6R* expression in multiple tissues including artery, colon, and esophagus was associated with increased<br>362 ris 361 IL6R expression in multiple tissues including artery, colon, and esophagus was associated with increase association of 362 ILEM expression in multiple tissues including artery, colon, and esophagus was associated with increased<br>362 ILEM expression in multiple tissues including artery, colon, and esophagus was associated with increased<br>363 363 lower risk of lower respiratory diseases and atopic dermatitis. Again, we observed opposite direction of<br>364 effect predicted by MR using monocyte or macrophage eQTL as exposure. The associations with<br>365 coronary athe 364 effect predicted by MR using monocyte or macrophage eQTL as exposure. The associations with<br>365 coronary atherosclerosis and AAA were further driven by a lead coding variant in *IL6R*, rs2228145<br>366 (Asp358Ala, **Additi** 365 coronary atherosclerosis and AAA were further driven by a lead coding variant in *IL6R*, rs222814!<br>366 (Asp358Ala, **Additional file 2: Table S10**). Finally, we found that increased *IL6ST* expression in T c<br>367 whole b 363 coronary atherosclerosis and AAA were rurther driven by a lead coding variant in IL6R, rs2228145<br>366 (Asp358Ala, **Additional file 2: Table S10**). Finally, we found that increased *IL6ST* expression in T ce<br>367 whole bl (Asp358Ala, Additional file 2: Table 310). Finally, we found that increased IL65T expression in Techs and<br>367 whole blood is predicted to increase the risk of rheumatoid arthritis, systemic connective tissue<br>368 disorders, 368 disorders, polyarthropathies, other arthritis, autoimmune diseases, and polymyalgia rheumatica<br>369 3A). The later association has not been reported previously to our knowledge. These association<br>370 driven by rs7731626 369 **3A**). The later association has not been reported previously to our knowledge. These associations were<br>370 driven by rs7731626 (SuSIE fine-mapping probability >0.99). This variant is located within an intron of<br>371 *A* 370 driven by rs7731626 (SuSIE fine-mapping probability >0.99). This variant is located within an intron of<br>371 ANKRD55 and colocalizes with eQTLs for both ANKRD55 and IL6ST (PP > 80%). However, this variant also<br>1 371 ANKRD55 and colocalizes with eQTLs for both ANKRD55 and IL6ST (PP > 80%). However, this variant all an introduced with eQTLs for both ANKRD55 and IL6ST (PP > 80%). However, this variant all and introduced with eQTLs fo 371 ANKRD55 and colocalizes with eQTLs for both ANKRD55 and IL6ST (PP > 80%). However, this variant also

(<br>|<br>ເ 373 boeinaps an enhancer that shows highest ABC score for IL6ST for genes in the region, suggesting the<br>373 latter is the causal gene, in line with previous studies[92, 93] (Figure 3B). Overall, our approach was<br>374 to cap to capture known associations with IL6-R related genes and identified a new association between *IL6ST*<br>and polymyalgia rheumatica.<br>376<br>**DISCUSSION** 374 to capture known associations with IL6-R related genes and identified a new association between IL6ST<br>375 and polymyalgia rheumatica.<br>376 DISCUSSION

376<br>377 **DISCUSSION**<br>378 We prioritized disease-associa ---<br>377<br>378<br>379<br>380 378 We prioritize<br>379 using a comb<br>380 annotations (<br>381 expression or 1379 using a combination of MR with molQTL, colocalization analysis, variant effect prediction, and epigene<br>380 annotations (ABC model). This approach allows the use of molQTL to infer directionality of gene<br>381 expression 380 annotations (ABC model). This approach allows the use of molQTL to infer directionality of gene<br>381 expression on disease risk, while improving the causal gene prediction compared to using molQTL alone.<br>382 Based on co Examples and the users (ABC model). This approach all the users of model is model in the users in the users of<br>Based on combination of these features, we used a ranking approach to prioritize genes within k<br>Showed that thi 382 Based on combination of these features, we used a ranking approach to prioritize genes within loci and<br>383 showed that this approach enriched for gold standard genes. We recover known coding variant<br>384 associations, i 383 showed that this approach enriched for gold standard genes. We recover known coding variant<br>384 associations, including rare variants in genes linked to monogenic disorders such as *PSEN1* and *APP1* and<br>385 Alzheimer' 384 associations, including rare variants in genes linked to monogenic disorders such as *PSEN1* and *A*<br>385 Alzheimer's disease, and *SQSTIM1* and Paget's disease (**Figure 1B**). Genes prioritized by molQTL<br>386 show enrich 385 Alzheimer's disease, and *SQSTIM1* and Paget's disease (Figure 1B). Genes prioritized by molQTL also<br>386 show enrichment in disease categories related to their function with pathogenic tissue contexts (Figure<br>387 1C-F) SECTED ALTHEIMER'S disease, and SQSTIM1 and Paget's disease (Figure 1B). Genes profitized by molQTL also<br>Show enrichment in disease categories related to their function with pathogenic tissue contexts (Figure 1C-F). Of not 387 **1C-F**). Of note, when multiple genes show evidence of colocalization within the same locus, the addition<br>388 of epigenetic (ABCmax) information can help prioritize one gene over the others. We note as an<br>389 example t 388 of epigenetic (ABCmax) information can help prioritize one gene over the others. We note as an<br>389 example the association of variants with polymyalgia rheumatica at the *ANRKD55* locus where this gene<br>390 would be pri Example the association of variants with polymyalgia rheumatica at the ANRKD55 locus where th<br>390 would be prioritized using the nearest gene approach. Whereas colocalization alone did not iden<br>391 single causal gene, comb Example the association of variants with polymyalgia incumaties at the ANRKD55 locus where this gene<br>390 would be prioritized using the nearest gene approach. Whereas colocalization alone did not identify a<br>391 single caus 391 single causal gene, combination of colocalization and ABCmax identified *IL6ST* as the putative causal<br>392 gene. To our knowledge, this is the first report of a GWAS association between *IL6ST* and polymyalgia<br>393 rheu 392 single causal gene, combination of colocalization and ABCmax identified I2657 as the putative causal<br>392 gene. To our knowledge, this is the first report of a GWAS association between IL6ST and polymyalgia<br>393 rheumati space. To our knowledge, this is the first report of a GWAS association between IL6ST and polymyalgia<br>393 rheumatica. *IL6ST* encodes a protein involved in signal transduction for the IL6 receptor pathway. 393 rheumatica. IL6ST encodes a protein involved in signal transduction for the IL6 receptor pathway.

19

 $\begin{array}{c} \n \text{I} \n \end{array}$ 

1395 In the ILF recent approval by the FDA.[94]<br>1396 In line with previous studies[11, 12], we show that therapeutic targets with genetic evidence are<br>1397 In line with previous studies[11, 12], we show that therapeutic ta 396 In line with previous studies[11,<br>397 enriched at later clinical trial pha<br>398 gene information alone was not<br>399 were coding variant annotations 397 enriched at later clinical trial phases and as targets of approved drugs. In our analysis, using the n<br>398 gene information alone was not strongly predictive of clinical trial success. The most predictive fe<br>399 were c 398 gene information alone was not strongly predictive of clinical trial success. The most predictive features<br>399 were coding variant annotations and ABC maps. While the later performs well to link causal genes to<br>390 dis 399 were coding variant annotations and ABC maps. While the later performs well to link causal genes to<br>399 diseases, it does not provide information about directionality. We used coding variants and MR with<br>301 molQTL to 399 diseases, it does not provide information about directionality. We used coding variants and MR with<br>399 molQTL to infer directionality of a target on disease risk. Both approaches were generally consistent<br>399 with dru 401 molQTL to infer directionality of a target on disease risk. Both approaches were generally consistent<br>402 with drug MoA matched for the target and disease. These data support that molQTL can be used to<br>403 predict drug with drug MoA matched for the target and disease. These data support that molQTL can be used to<br>403 predict drug MoA. However, while we found that in general eQTL were consistent across cell type an<br>404 tissues for a given 403 predict drug MoA. However, while we found that in general eQTL were consistent across cell type artissues for a given gene and disease (Additional file 1: Figure S5), we note that this isn't always the used to This is 404 tissues for a given gene and disease (**Additional file 1: Figure S5**), we note that this isn't always the cas<br>405 This is exemplified by the IL6-R case study, where all three queried gene displayed inconsistent directi This is exemplified by the IL6-R case study, where all three queried gene displayed inconsistent direction<br>406 of effect predicted by MR depending on the molQTL dataset. Future improvement of this approach<br>407 should consi 406 of effect predicted by MR depending on the molQTL dataset. Future improvement of this approach<br>407 should consider prior knowledge on pathogenic cell types or tissues to infer directionality in relevant<br>408 contexts. O 407 should consider prior knowledge on pathogenic cell types or tissues to infer directionality in relevant contexts. Overall, our analysis suggests that using features such as ABCmax in combination to molQ<br>409 can increas 208 contexts. Overall, our analysis suggests that using features such as ABCmax in combination to molQTI<br>209 can increase the performance of causal gene inference approaches while informing on directionality<br>210 which is c 208 can increase the performance of causal gene inference approaches while informing on directionality<br>210 which is crucial for translating GWAS hits to therapies.<br>211 We note that this study has some limitations. First, w

which is crucial for translating GWAS hits to therapies.<br>411 We note that this study has some limitations. First, we did not perform fine-mapping analyses nor<br>412 colocalization approaches that use linkage disequilibrium r 411 We note that this study has some limitations. First, we<br>412 colocalization approaches that use linkage disequilibriu<br>413 methods that do not rely on LD references as we used (<br>414 analyses where these methods may not b 112 Colocalization approaches that use linkage disequilibrium references. Indeed, we opted to avoid<br>113 methods that do not rely on LD references as we used GWAS from various sources, including meta<br>114 analyses where thes methods that do not rely on LD references as we used GWAS from various sources, including me<br>analyses where these methods may not be well calibrated. [95] Nevertheless, using fine-mapping<br>information likely would improve p 414 analyses where these methods may not be well calibrated.[95] Nevertheless, using fine-mapping variants underlying molQTL or GWAS signals, and would reduce LD contamination [30, 96]. In additi<br>417 we performed MR and colocalization analyses as separate steps. Tools that use a combination of there are multiple causal we performed MR and colocalization analyses as separate steps. Tools that use a combination of these<br>417 we performed MR and colocalization analyses as separate steps. Tools that use a combination of these  $\frac{4}{17}$  we performed MR and colocalization analyses as separate steps. Tools that use a combination of these comb

ة<br>|<br>ا 419 heterogeneity[97]. This is evident in the case of *IL6ST*, where MR using eQTL from whole bloom<br>420 different sources (GTEx, eQTLGen) lead to inversed estimate of directionality (**Figure 3A**). This<br>421 was due to diffe different sources (GTEx, eQTLGen) lead to inversed estimate of directionality (**Figure 3A**). This different<br>was due to different instrument used as only one genetic instrument was included in GTEx whereas 5<br>independent ins was due to different instrument used as only one genetic instrument was included in GTEx whereas 5<br>independent instruments were included for eQTLGen. We also assume that there is one causal gene per<br>locus, although it is p independent instruments were included for eQTLGen. We also assume that there is one causal gene p<br>locus, although it is possible that multiple genes contribute to disease risk. Finally, integrating other<br>sources of molQTL Independent instruments were the disease risk. Finally, integrating other<br>124 sources of molQTL such as metabolite or splice QTL could help identify putative causal genes as coding<br>125 variants and eQTL only cover a fracti 1244 sources of molQTL such as metabolite or splice QTL could help identify putative causal genes as codi<br>
1425 variants and eQTL only cover a fraction of loci (18-45% in this study). [98] While these approaches ca<br>
1426 u 425 variants and eQTL only cover a fraction of loci (18-45% in this study).[98] While these approaches can b<br>426 useful to nominate candidate causal genes and their relationship to diseases, proper functional<br>427 validatio 426 useful to nominate candidate causal genes and their relationship to diseases, proper functional<br>427 validation remains of high importance.<br>428 CONCLUSIONS 427 validation remains of high importance.<br>428<br>428 **CONCLUSIONS** 428<br>429 **CONCLUSIONS**<br>430 We nominated putative causal genes ad 429<br>430<br>431<br>432 430 We nominated<br>431 integrating vari<br>432 known biologic:<br>433 therapeutic targ 431 Integrating variant annotations as well as molecular QTL. We show that these prioritized genes recover<br>432 known biological relationships in terms of disease and tissue enrichment and are enriched for<br>433 therapeutic t 432 known biological relationships in terms of disease and tissue enrichment and are enriched for<br>433 therapeutic targets that succeeded in clinical trials. We show that directionality predicted by molQTL<br>434 and coding va therapeutic targets that succeeded in clinical trials. We show that directionality predicted by n<br>and coding variants generally recapitulate drug mechanism of actions. Finally, we applied this<br>to genes related to the IL6 r 434 and coding variants generally recapitulate drug mechanism of actions. Finally, we applied this approaction<br>435 to genes related to the IL6 receptor and identified a novel association between *IL6ST* and polymyalgial<br>43 to genes related to the IL6 receptor and identified a novel association between *IL6ST* and polymyalgia<br>
436 rheumatica supporting the recent approval of Sarilumab for this indication.<br>
437 **ARREVIATIONS** to genes related to the IL6 receptor and identified a novel association between IL6ST and polymyalgia<br>
A36 theumatica supporting the recent approval of Sarilumab for this indication.<br>
A37 **ABBREVIATIONS** 437<br>438 **ABBREVIATIONS** 

438<br>|
|

- 
- 
- $\frac{1}{2}$ 440 factor ontology; eQTL: Expression quantitative trait loci; EstBB: Estonian Biobank; GWAS: Genome-wid<br>441 association study; GoF: Gain of function; GoLoF: Gain or loss of function; HLA: Human leukocyte antige<br>442 iPSC: 441 association study; GoF: Gain of function; GoLoF: Gain or loss of function; HLA: Human leukocyte antigen;<br>142 iPSC: Induced Pluripotent Stem Cells; LCL: Lymphoblastoid cell lines; LD: Linkage disequilibrium; LoF:<br>143 Lo
- 
- 
- 1442 IPSC: Induced Pluripotent Stem Cells; LCL: Lymphoblastoid cell lines; LD: Linkage disequilibrium; LoF:<br>1443 Loss of function; MAF: Minor allele frequency; MoA: Mechanism of action; MR: Mendelian<br>1444 Trandomization; m 1442 Ioss of function; MAF: Minor allele frequency; MoA: Mechanism of action; MR: Mendelian<br>1444 Ioss of function; molQTL: Molecular quantitative trait loci; OR: Odds ratio; pQTL: Protein quantitative<br>1445 Iossinic per pro randomization; molQTL: Molecular quantitative trait loci; OR: Odds ratio; pQTL: Protein quantitative trait loci; MR: Misk ratio; UKB: UK Biobanism of action; Mariant effect predictor.
- 1445 trait loci; PP: posterior probability; QTL: Quantitative trait loci; RR: Risk ratio; UKB: UK Biobank; VEP:<br>1446 Variant effect predictor.
- 446 Variant effect predictor.<br>
2446 Variant effect predictor. 446 Variant effect predictor.

448



23

# |
|
|
| Features used to prioritize genes in GWAS loci. Genes are ranked based on a combination of featur<br>Including molQTLs, activity-by-contact (ABC) maps, and variant annotations, including variant effec<br>Including molQTLs, activ including molQTLs, activity-by-contact (ABC) maps, and variant annotations, including variant effect<br>452 predictions (VEP) and loss-of-function (LoF) and gain-of-function (GoF) predictions. **B)** Disease-<br>453 associated pre predictions (VEP) and loss-of-function (LoF) and gain-of-function (GoF) predictions. **B)** Disease-<br>associated predicted GoF and LoF variants captures disease associations with high effect sizes. Lead<br>and LoF variant with G and LoF variant with GWAS P-value <  $5x10^{-8}$  are reported in the figure. Effect of the risk allele (odds<br>ratio) is reported on the y-axis. The x-axis corresponds to the frequency of the risk allele. C) Disease<br>dategory o and LoF variant with GWAS P-value < 5x10 ° are reported in the figure. Effect of the risk allele (odds<br>ratio) is reported on the y-axis. The x-axis corresponds to the frequency of the risk allele. C) Disease<br>dategory overr category overrepresentation for single genes predicted to be causal. Each dot represents a different<br>associated disease category. Top 30 enrichments are shown. **D)** Same as B, but filtered for genes<br>predicted to be causal associated disease category. Top 30 enrichments are shown. **D)** Same as B, but filtered for genes<br>predicted to be causal and enriched in "Immune system diseases". Each dot represents a different<br>associated disease category predicted to be causal and enriched in "Immune system diseases". Each dot represents a differer<br>associated disease category. Top 30 genes are shown. **E)** Overrepresentation of eQTL colocalization<br>single genes predicted to associated disease category. Top 30 genes are shown. **E)** Overrepresentation of eQTL colocalization<br>460 single genes predicted to be causal. Gene-tissue pairs are included only if the gene has the highest in a locus for a 14460 single genes predicted to be causal. Gene-tissue pairs are included only if the gene has the highest rank<br>1461 in a locus for a given associated disease. Top 30 colocalized eQTLs are shown. Each dot represents a<br>1462 1461 in a locus for a given associated disease. Top 30 colocalized eQTLs are shown. Each dot represents a different enriched tissue or cell-type. F) Enriched colocalizing cell types and tissues by disease categories. Only different enriched tissue or cell-type. F) Enriched colocalizing cell types and tissues by disease<br>categories. Only disease categories and tissues or cell types with at least one significant enrichment<br>reported in the heat categories. Only disease categories and tissues or cell types with at least one significant enrich<br>
464 reported in the heatmap. Enrichment P-values are calculated using Fisher exact test, testing fo<br>
465 enrichment of gen 1444 reported in the heatmap. Enrichment *P*-values are calculated using Fisher exact test, testing for the<br>1465 enrichment of genes with eQTL colocalizing with GWAS belonging to specific disease categories as in<br>1466 [79] 1644 reported in the heatmap. Ennement P-values are calculated using Fisher exact test, testing for the<br>165 enrichment of genes with eQTL colocalizing with GWAS belonging to specific disease categories as in<br>166 [79]. Tiss 1466 [79]. Tissues and cell-types were collapsed into broader categories before testing for enrichment. For<br>1467 example, tibial, coronary, and aorta arteries were grouped into "artery".<br>1468 molQTL: Molecular QTL; ABC: Ac example, tibial, coronary, and aorta arteries were grouped into "artery".<br>
1468 molQTL: Molecular QTL; ABC: Activity-By-Contact; LCL: Lymphoblastoid cell lines; iPSC: induced<br>
1470 Adiusted P<0.1<sup>.\*</sup> Adiusted P<0.05<sup>.\*\*</sup> A

468 molQTL: Molecular QTL; ABC: Activity-By-Contact; LCL: Lymphoblastoid coronation Pluripotent Stem Cells<br>469 Pluripotent Stem Cells<br>470 : Adjusted P<0.1; \*: Adjusted P<0.05; \*\*: Adjusted P<0.01; \*\*\*: Adjusted Pluripotent Stem Cells<br>469 moldtient Stem Cells<br>470 :: Adjusted P<0.1; \*: Adjusted P<0.05; \*\*: Adjusted P<0.01; \*\*\*: Adjusted P<0.001<br>471

470  $\;$  .: Adjusted P<0.1;  $*$  : Ad<br>471 470 .: Adjusted P<0.1; \*: Adjusted P<0.05; \*\*: Adjusted P<0.01; \*\*\*: Adjusted P<0.001

It is made available under a CC+BY-NC-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.11.01.23297926;](https://doi.org/10.1101/2023.11.01.23297926) this version posted November 1, 2023. The copyright holder for this preprint



473<br>474<br>475<br>476<br>477 drugs in clinical trials (phase I-III) using genetic evidence from FinnGen, UK Biobank, and biobank me<br>analyses prioritizing genes using colocalization (posterior probability of colocalization [H4] > 80% or<br>95%), predicted 480 direction of effect of lead low-frequency coding variants on disease risk, and drug mechanism of action 476 95%), predicted gain of function (GoF) or loss of function (LoF) variants[47], genes with highest<br>477 prioritization rank, ABC score for lead variant, or nearest gene excluding loci with associated coding<br>478 variants. prioritization rank, ABC score for lead variant, or nearest gene excluding loci with associated comprise variants. **B)** Enrichment of targets of approved drugs or drugs in clinical trials (phase I-III) using gene prioritiz variants. **B)** Enrichment of targets of approved drugs or drugs in clinical trials (phase I-III) using cause<br>gene prioritization ranks in FinnGen, UK Biobank, and biobank meta-analyses. **C)** Concordance between<br>direction o 479 gene prioritization ranks in FinnGen, UK Biobank, and biobank meta-analyses. C) Concordance betwee<br>direction of effect of lead low-frequency coding variants on disease risk, and drug mechanism of action<br>direction of ef 479 gene prioritization ranks in FinnGen, OK Biobank, and biobank meta-analyses. C) concordance between<br>direction of effect of lead low-frequency coding variants on disease risk, and drug mechanism of action<br>2  $480$  direction of leads low-frequency coding variants on  $\frac{1}{2}$ 

(<br>|
|
| trials, and drug MoA from the Citeline Pharmacogenomics dataset. We connected this dataset to GV<br>phenotypes using EFO codes and a semantic similarity score > 0.7. We assume that low-frequency<br>coding variants (minor allele phenotypes using EFO codes and a semantic similarity score > 0.7. We assume that low-frequency<br>coding variants (minor allele frequency < 5%) are disruptive (LoF). Therefore a negative (protective)<br>direction of effect would Frame, presenting EFT controlled and a semantic similarly score - 1.14.14.2 and a matrice in trapletity<br>
484 coding variants (minor allele frequency < 5%) are disruptive (LoF). Therefore a negative (protective<br>
485 directi direction of effect would translate into inhibition or antagonism being beneficial (and vice-versa). **D**<br>Concordance between the predicted impact of gene expression on disease risk predicted by mendel<br>randomization (MR), a 486 Concordance between the predicted impact of gene expression on disease risk predicted by mendelia<br>487 randomization (MR), and drug MoA for targets in phase II clinical trials or above. Information about<br>488 targets, cl 1487 concording the predicted impact of gene expression in an extending predicted in mention about<br>1488 targets, clinical trials, and drug MoA were collected from the Citeline Pharmacogenomics dataset and<br>1489 connected to targets, clinical trials, and drug MoA were collected from the Citeline Pharmacogenomics dataset an<br>connected to GWAS phenotypes using EFO codes and a semantic similarity score > 0.7. The direction<br>effect of gene expressio 288 targets, connected to GWAS phenotypes using EFO codes and a semantic similarity score > 0.7. The direction connected to GWAS phenotypes using EFO codes and a semantic similarity score > 0.7. The direction conferenct of 490 effect of gene expression on disease risk was assessed by MR using molQTL as exposure (q-value < 0.05)<br>491 Only molQTL colocalizing with local GWAS signal (H4 posterior probability > 80%) were included. A<br>492 consensus 0 effect only molQTL colocalizing with local GWAS signal (H4 posterior probability > 80%) were included. A<br>492 consensus direction was inferred if the MR direction of effect was consistent across > 75% of molQTL for<br>493 a 2012 Consensus direction was inferred if the MR direction of effect was consistent across > 75% of molQ<br>2013 a given gene and disease GWAS. A negative consensus MR direction suggests that increased gene<br>2014 expression lea a given gene and disease GWAS. A negative consensus MR direction suggests that increased gene<br>expression leads to decreased disease risk. Therefore, an activator or agonist drug targeting this gene<br>would be beneficial. Con expression leads to decreased disease risk. Therefore, an activator or agonist drug targeting this g<br>would be beneficial. Conversely, a positive consensus MR direction suggests that increased gene<br>expression increases dise 495 would be beneficial. Conversely, a positive consensus MR direction suggests that increased gene<br>
496 expression increases disease risk, and an inhibitor or antagonist drug would be beneficial. Reported *P*-<br>
497 value expression increases disease risk, and an inhibitor or antagonist drug would be beneficial. Report<br>values were calculated by Fisher exact test.<br>498 ...: P<0.1; \*: P<0.05; \*\*: P<0.01; \*\*\*: P<0.001 496 expression increases disease risk, and an inhibitor or antagonist drug would be beneficial. Reported P-<br>
values were calculated by Fisher exact test.<br>
498 ... P<0.1; \*: P<0.05; \*\*: P<0.01; \*\*\*: P<0.001 498  $\therefore P < 0.1; * : P < 0.05; * * : P < 0.01; * * * : P < 0.001$ <br>499

498 .: P<0.1; \*: P<0.05; \*\*: P<0.01; \*\*\*: P<0.001

26





501<br>502<br>503<br>504<br>505 502 Diseases associations supported by MR, colocalization and ABC. thows tissues and cell-types with<br>503 significant MR (q-value < 0.05) using *IL6ST* eQTL as exposure and diseases as outcome (red: positive<br>504 effect size significant MR (q-value < 0.05) using *IL6ST* eQTL as exposure and diseases as outcome (red: positive effect size estimate [MR beta]; blue: negative effect size estimate). The size of the dots represents absolute effect si Example of the size of the dots represents<br>
503 effect size estimate [MR beta]; blue: negative effect size estimate). The size of the dots represents<br>
505 absolute effect size. Disease-eQTL pairs with a colocalization post absolute effect size. Disease-eQTL pairs with a colocalization posterior probability > 80% are highlig<br>with a dark border. **B)** LocusZoom[83] plot showing the top association for polymyalgia rheumatica<br>the *ANKRD55-IL6ST* with a dark border. **B)** LocusZoom[83] plot showing the top association for polymyalgia rheumatica at<br>the *ANKRD55-IL6ST* locus. Both *IL6ST* and *ANKRD55* eQTL colocalize with the polymyalgia rheumatica<br>signal, but *IL6ST* 507 with a dark border. B) LocusZoom[63] plot showing the top association for polymyalgia rheumatica at<br>508 the ANKRD55-IL6ST locus. Both IL6ST and ANKRD55 eQTL colocalize with the polymyalgia rheumatica<br>508 signal, but IL 508 signal, but *IL6ST* has the highest ABC score.<br>509  $509$ 







520 molQTL: molecular QTL; N: Number

542 and Terveystalo Biobank STB 2018001.

|
|
| 522 Ethics approval and correctly and correctly and correctly are interestingly and correctly are interestingly came into effect the correct of the Figure 2022<br>523 Patients and control subjects in FinnGen p<br>524 Finnish Biobank Act. Alternatively, separa<br>525 came into effect (in September 2013) an<br>526 study-specific consents and later transfe Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish Biobank Act<br>S25 came into effect (in September 2013) and start of FinnGen (August 2017), were collected based on<br>S26 study-specific 525 came into effect (in September 2013) and start of FinnGen (August 2017), were collected based on<br>526 study-specific consents and later transferred to the Finnish biobanks after approval by Fimea, the<br>527 National Super 526 study-specific consents and later transferred to the Finnish biobanks after approval by Fimea, the<br>527 National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank<br>528 protocols app Similar Study-specific consents and manufactured to the Finnish biological consequences in National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank<br>S28 protocols approved by Fimea. 528 protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and<br>529 Uusimaa (HUS) approved the FinnGen study protocol Nr HUS/990/2017.<br>530 The FinnGen study is approved by Finnis

529 Uusimaa (HUS) approved the FinnGen study protocol Nr HUS/990/2017.<br>530 The FinnGen study is approved by Finnish Institute for Health and Welfare (permit numbers:<br>531 THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/34 530 The FinnGen study is approved by Finnish Institute for Health a<br>531 THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2<br>532 THL/283/6.02.00/2019, THL/1721/5.05.00/2019, THL/1524/5.05.00/202<br>533 Digital and 531 THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018,<br>532 THL/283/6.02.00/2019, THL/1721/5.05.00/2019, THL/1524/5.05.00/2020, and THL/2364/14.02/2020),<br>533 Digital and population da THL/283/6.02.00/2019, THL/1721/5.05.00/2019, THL/1524/5.05.00/2020, and THL/2364/14.02/2020),<br>533 Digital and population data service agency (permit numbers: VRK43431/2017-3, VRK/6909/2018-3,<br>754 VRK/4415/2019-3), the Soci Digital and population data service agency (permit numbers: VRK43431/2017-3, VRK/6909/2018-3,<br>S34 VRK/4415/2019-3), the Social Insurance Institution (permit numbers: KELA 58/522/2017, KELA<br>131/522/2018, KELA 70/522/2019, K USER 131/522/2019-3), the Social Insurance Institution (permit numbers: KELA 58/522/2017, KELA<br>131/522/2018, KELA 70/522/2019, KELA 98/522/2019, KELA 138/522/2019, KELA 2/522/2020, KELA<br>16/522/2020 and Statistics Finland ( 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, KELA 138/522/2019, KELA 2/522/2020, KELA<br>536 16/522/2020 and Statistics Finland (permit numbers: TK-53-1041-17 and TK-53-90-20).<br>537 The Biobank Access Decisions for FinnGe

16/522/2020 and Statistics Finland (permit numbers: TK-53-1041-17 and TK-53-90-20).<br>537 The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze 6 include:<br>538 THL Biobank BB2017\_55, BB2017 537 The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data<br>538 THL Biobank BB2017\_55, BB2017\_111, BB2018\_19, BB\_2018\_34, BB\_2018\_67, BB201<br>539 BB2019\_8, BB2019\_26, BB2020\_1, Finnish Red Cross Bl 538 THL Biobank BB2017\_55, BB2017\_111, BB2018\_19, BB\_2018\_34, BB\_2018\_67, BB2018\_71, BB2019\_7,<br>539 BB2019\_8, BB2019\_26, BB2020\_1, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank<br>540 HUS/359/2017, Auria BB2019\_8, BB2019\_26, BB2020\_1, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank<br>540 HUS/359/2017, Auria Biobank AB17-5154, Biobank Borealis of Northern Finland\_2017\_1013, Biobank of<br>541 Eastern Finland 1 539 BB2019\_8, BB2019\_26, BB2020\_1, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank 541 Eastern Finland 1186/2018, Finnish Clinical Biobank Tampere MH0004, Central Finland Biobank 1-2017,<br>312 and Terveystalo Biobank STB 2018001.<br>30 542 and Terveystalo Biobank STB 2018001.<br>30<br>30



It is made available under a COBBY-IMC-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.11.01.23297926;](https://doi.org/10.1101/2023.11.01.23297926) this version posted November 1, 2023. The copyright holder for this preprint

- $rac{6}{3}$ 566 SL, MC, MB, SS, CC, E<br>567 options in the compa<br>568 Services at the time of
- 566 SL, MC, MB, SS, CC, EdR, KK, JS, SK are employees of Sanofi US Services and hold shares and/or stock
- 568 Services at the time of study. All authors declare no other competing interests.<br>569<br>570 <u>Funding</u>

- 570<br>571<br>572
- 569<br>570 Funding<br>571 This study was funded by Sanofi (Cambridge, MA, United States). The funder had 571 This students<br>571 This students<br>573 The Finn<br>574 4386/31
- 
- 572 Involvement with the study: Sanofi reviewed the manuscript.<br>573 The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH<br>574 4386/31/2016) and the following industry partners: AbbVie I 573 The FinnGen project is funded by two grants from Business Fir<br>574 4386/31/2016) and the following industry partners: AbbVie In<br>575 Celgene Corporation, Celgene International II Sàrl, Genentech<br>576 Inc., GlaxoSmithKline
- 574 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA<br>575 Celgene Corporation, Celgene International II Sàrl, Genentech Inc., Merck Sharp & Dohme Corp,<br>576 Inc., GlaxoSmithKline
- 575 Celgene Corporation, Celgene International II Sàrl, Genentech Inc., Merck Sharp & Dohme Corp, Pfizer<br>1576 Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeut<br>1577 Inc.,
- 1999 Corporation, Celgene International International II Systems Corp, Corporation Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutin<br>
Inc., Janssen Biotech Inc. and Nov
- 

586 Project No. 2014-2020.4.01.16-0125.

- 1999 Inc., Janssen Biotech Inc, and Novartis AG.<br>1978 UK Biobank is supported by its founding funders the Wellcome Trust and UK Medical Research Council,<br>1979 as well as the Department of Health, Scottish Government, the N
- 
- 578 UK Biobank is supported by its founding fu<br>579 as well as the Department of Health, Scotti<br>580 Agency, British Heart Foundation and Canc<br>581 Fstonian Biobank research was supported

579 as well as the Department of Health, Scottish Government, the Northwest Regional Development<br>580 Agency, British Heart Foundation and Cancer Research UK.<br>581 Estonian Biobank research was supported by the European Unio Extending May are research was supported by the European Union through Horizon 2020 research<br>1981 Estonian Biobank research was supported by the European Union through Horizon 2020 research<br>1982 Innovation programme under 581 Estonian Biobank research was supported by the European<br>582 Innovation programme under grant no 810645 and through<br>583 Innovation and Cancer Research Council gior<br>584 Innovation Cancer Research Council gior and by the Estonian Biotenian Biotenian Biotenian Biotenian Biotenian Regional Development Fund<br>
582 Innovation programme under grant no 810645 and through the European Regional Development Fund<br>
583 Project no. MOBEC008, by the Esto 583 project no. MOBEC008, by the Estonian Research Council grant PUT (PRG1291, PRG687 and PRG184)<br>584 and by the European Union through the European Regional Development Fund project no. MOBERA21<br>585 (ERA-CVD project DETEC 584 and by the European Union through the European Regional Development Fund project no. MOBERA2<br>585 (ERA-CVD project DETECT ARRHYTHMIAS, GA no JTC2018-009), Project No. 2014-2020.4.01.15-0012 a<br>586 Project No. 2014-2020.4 585 (ERA-CVD project DETECT ARRHYTHMIAS, GA no JTC2018-009), Project No. 2014-2020.4.01.15-0012 an<br>586 Project No. 2014-2020.4.01.16-0125. 586 Project No. 2014-2020.4.01.16-0125.

587

# $\frac{1}{2}$ ---<br>588<br>589<br>590<br>591



- 
- 
- 
- 589 contributors in writing the manuscript. FinnGen authors defined endpoints, performed GWAS,<br>591 generated summary statistics, and performed meta-analyses. Estonian Biobank authors defined<br>592 matching disease endpoints, 591 generated summary statistics, and performed meta-analyses. Estonian Biobank authors defined<br>592 matching disease endpoints, performed GWAS and generated EstBB summary statistics. MB ac<br>593 and formatted data and perfor 592 matching disease endpoints, performed GWAS and generated EstBB summary statistics. MB acq<br>593 and formatted data and performed data analysis. SS, KK, EdR, JS, SK, DR designed the study, inte<br>594 results, and contribute and formatted data and performed data analysis. SS, KK, EdR, JS, SK, DR designed the study, interpreted results, and contributed to writing the manuscript. All authors read and approved the final manuscript.<br>595<br>595 Acknow
- 594 results, and contributed to writing the manuscript. All authors read and approved the final manuscript.<br>595<br>596 Acknowledgments

595<br>595 Acknowledgments<br>597 We thank all participants and contributors to the datasets used in this study. We thank Hao He (Sanofi ---<br>596<br>597<br>598<br>599 597 We thank all partic<br>598 US) for his valuable<br>599 ontology mapping.<br>600 UK Biobank 598 US) for his valuable feedback on the manuscript, and Omar Stradella (Sanofi US) for his support with<br>599 ontology mapping.<br>600 UK Biobank<br>601 This research has been conducted using the UK Biobank Besource (www.ukhioban

599 ontology mapping.<br>599 UK Biobank<br>601 This research has been conducted using the UK Biobank Resource (www.ukbiobank.ac.uk), a large-sc<br>502 biomedical database and research resource containing genetic. lifestyle and heal Example of the B<br>599 ontology MK Biobank<br>501 biomedical databas<br>503 500 000 UK particing 600 UK Biobank<br>601 This researc<br>603 500,000 UK<br>604 Medical Res 602 biomedical database and research resource containing genetic, lifestyle and health information from<br>603 500,000 UK participants. UK Biobank is supported by its founding funders the Wellcome Trust and UK<br>604 Medical Res 603 500,000 UK participants. UK Biobank is supported by its founding funders the Wellcome Trust and UK<br>604 Medical Research Council, as well as the Department of Health, Scottish Government, the Northwest<br>605 Regional Deve Medical Research Council, as well as the Department of Health, Scottish Government, the Northwest<br>Regional Development Agency, British Heart Foundation and Cancer Research UK. The UK biobank par<br>ancestry analysis was condu Regional Development Agency, British Heart Foundation and Cancer Research UK. The UK biobank partment of Analysis was conducted under project ID 31063 (https://pan.ukbb.broadinstitute.org).<br>Finn Gorden<br>Finn Gen 607 FinnGen<br>607 FinnGen

607 FinnGen

- 
- 
- $\begin{array}{c} \n\frac{1}{2} & \text{if } \\ \n\frac{$ 609 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA<br>610 Celgene Corporation, Celgene International II Sàrl, Genentech Inc., Merck Sharp & Dohme Corp,<br>611 Inc., GlaxoSmithKline
- 
- 
- Celgene Corporation, Celgene International II Sàrl, Genentech Inc., Merck Sharp & Dohme Corp, Pfizer<br>11 Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeut<br>12 Inc., Janssen Figure Corporation, Celgene International International II, Methology Pressure Corp, Maze Therapeuti<br>
Inc., Janssen Biotech Inc, and Novartis AG. Following biobanks are acknowledged for delivering biobank<br>
Samples to FinnG For the University of the University Property Property States Inc., Janssen Biotech Inc, and Novartis AG. Following biobanks are acknowledged for delivering biobank<br>Samples to FinnGen: Auria Biobank (www.auria.fi/biopankki 613 samples to FinnGen: Auria Biobank (<u>www.auria.fi/biopankki</u>), THL Biobank (<u>www.thl.fi/biobank),</u> Helsink<br>614 Biobank (<u>www.helsinginbiopankki.fi),</u> Biobank Borealis of Northern Finland<br>615 (https://www.ppshp.fi/Tutkim
- 
- 614 Biobank (www.helsinginbiopankki.fi), Biobank Borealis of Northern Finland<br>615 (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx),<br>616 Finnish Clinical Biobank Tampere (ww 615 (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borea<br>616 Finnish Clinical Biobank Tampere (www.tays.fi/en-<br>617 US/Research\_and\_development/Finnish\_Clinical\_Biobank\_Tampere), Bioba<br>618 (www.ita-suomenb
- 
- 
- Finnish Clinical Biobank Tampere (www.tays.fi/en-<br>617 (US/Research\_and\_development/Finnish\_Clinical\_Biobank\_Tampere), Biobank of Eastern Finland<br>618 (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi
- 
- Finnish Red Cross Blood Service Biobank (www.weripalvelu.fi/verenluovutus/biopankkitoiminta) a<br>619 Finnish Red Cross Blood Service Biobank (www.veripalvelu.fi/verenluovutus/biopankkitoiminta) a<br>620 Terveystalo Biobank (www Finnish Red Cross Blood Service Biobank (www.veripalvelu.fi/verenluovutus/biopankkitoiminta) and<br>620 Terveystalo Biobank (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/). All<br>621 Finnish Biobanks are Finnish Riobank (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/). All<br>621 Finnish Biobanks are members of BBMRI.fi infrastructure (www.bbmri.fi). Finnish Biobank Cooperativ<br>622 FINBB (https://finbb.fi
- Finnish Biobanks are members of BBMRI.fi infrastructure (www.bbmri.fi). Finnish Biobank Coopera<br>622 FINBB (https://finbb.fi/) is the coordinator of BBMRI-ERIC operations in Finland.<br>623 Estonian Biobank<br>624 Estonian Bioban
- 
- 
- FINBB (https://finbb.fi/) is the coordinator of BBMRI-ERIC operations in Finland.<br>623 Estonian Biobank<br>624 Estonian Biobank research was supported by the European Union through Horizon 2020 research and<br>625 innovation prog Extending Biobank<br>623 Finding Biobank<br>624 Estonian Biobank research was supported by the European Union through Horizon<br>625 Innovation programme under grant no 810645 and through the European Region<br>626 Innovation programm
- 
- 
- 623 Estonian Biobank<br>624 Estonian Biobank<br>626 project no. MOBE<br>627 and by the Europe 625 innovation programme under grant no 810645 and through the European Regional Development Func<br>626 project no. MOBEC008, by the Estonian Research Council grant PUT (PRG1291, PRG687 and PRG184)<br>627 and by the European Un For the European Union through the European Regional Development Fund project no. MOBECOO8, by the Estonian Research Council grant PUT (PRG1291, PRG687 and PRG184)<br>and by the European Union through the European Regional De 627 and by the European Union through the European Regional Development Fund project no. MOBERA2<br>628 (ERA-CVD project DETECT ARRHYTHMIAS, GA no JTC2018-009), Project No. 2014-2020.4.01.15-0012 a<br>629 Project No. 2014-2020.4
- 628 (ERA-CVD project DETECT ARRHYTHMIAS, GA no JTC2018-009), Project No. 2014-2020.4.01.15-0012 an<br>629 Project No. 2014-2020.4.01.16-0125. Computations were performed in the High Performance<br>630 Computing Center, Universit
- Franchine project No. 2014-2020.4.01.16-0125. Computations were performed in the High Performance<br>
Computing Center, University of Tartu.<br>
34
- 630 Computing Center, University of Tartu.<br>
Example 2014-2020.<br>
The High Performance performance performance performance in the High Performance of High Performance Performance Performance Performance Performance Performan 630 Computing Center, University of Tartu.



feature and GWAS study source. Table S2: Precision and recall of different features to recover gold standard general sta 652 feature and GWAS study source. Table S2: Precision and recall of different features to recover gold

- 
- 
- ؟<br>)<br>) 654 Genes with overrepresented disease categories of GWAS in which they are prioritized as causal. Taket S5: Genes with overrepresented cell-type colocalizing QTL with GWAS in which they are prioritized causal. Table S6: S 655 S5: Genes with overrepresented cell-type colocalizing QTL with GWAS in which they are prioritized as<br>656 causal. Table S6: Significantly enriched colocalizing QTL cell types and tissues in disease GWAS<br>657 categories,
- 
- 
- 
- Example 2012 1916 States with overlaying the set of the states with the matter are protected causal. Table S6: Significantly enriched colocalizing QTL cell types together. Table S7: Significantly enriched colocalizing QTL Example Secure Security 2012 can alter the security of the security of the security enriched colocalizing QTL cell types and tissues in disease GWAS categories, treating each eQTL dataset separately. Table S8: Enrichment o 658 colocalizing QTL cell types and tissues in disease GWAS categories, treating each eQTL dataset<br>659 separately. Table S8: Enrichment of prioritized genes by feature across clinical trial phases and ap<br>660 drugs. Table S 659 separately. Table S8: Enrichment of prioritized genes by feature across clinical trial phases and<br>660 drugs. Table S9: Enrichment of prioritized genes by rank across clinical trial phases and approv<br>661 Table S10: Caus
- drugs. Table S9: Enrichment of prioritized genes by rank across clinical trial phases and approved drugs.<br>
Table S10: Causal association between diseases and IL6, IL6ST, or IL6R.<br>
Additional file 3: FinnGen banner authors
- 
- Table S10: Causal association between diseases and IL6, IL6ST, or IL6R.<br> **Additional file 3: FinnGen banner authors and affiliations.** List of FinnGen authors and their affiliations.<br> **Additional file 4: Funding statements** Mart Carl State Microsom accured and accured many, 1999, 2019.<br> **Additional file 3: FinnGen banner authors and affiliations.** List of Finn<br> **Additional file 4: Funding statements for eQTL and pQTL datasets.** Fur<br>
for all e
- Additional file 4: Funding statements for eQTL and pQTL datasets. Funding statements and references<br>664 for all eQTL and pQTL datasets used for this manuscript.<br>REFERENCES<br>REFERENCES
- 

- For all eQTL and pQTL datasets used for this manuscript.<br>
For all eQTL and pQTL datasets used for this manuscript.<br> **REFERENCES**<br>
2 Additional File 15 years of genome-wide association studies and no signs of slowing down REPRENCES<br>
665 REFERENCES<br>
666 1. Visscher PM, Wray NR, Zhang Q, Sklar P, McCartl<br>
667 **Discovery: Biology, Function, and Translation.**<br>
668 2. Loos RJF: **15 years of genome-wide association** s<br>
669 *Commun* 2020, **11:**590
- 
- 666 1. Vissch<br>667 **Disco**<br>668 2. Loos F<br>669 *Comm*<br>670 3. Bunie<br>671 J, Mot<br>672 associ Discovery: Biology, Function, and Translation. Am J Hum Genet 2017, 101:5-22.<br>
Coos RJF: 15 years of genome-wide association studies and no signs of slowing down. Nat<br>
Commun 2020, 11:5900.<br>
3. Buniello A, MacArthur JAL, C Exercisy: Biology, Function, and Translation: Am J Hum Genet 2017, 101:5-22.<br>
668 2. Loos RJF: **15 years of genome-wide association studies and no signs of slowing (**<br>
669 60 670 3. Buniello A, MacArthur JAL, Cerezo M, Har Ecos RJF: 15 years of genome-wide association studies and no signs of slowing down. Nat<br>
Commun 2020, 11:5900.<br>
3. Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, McMahon A, Mo<br>
1, Mountjoy E, Soll 670 3. Buniello A, MacArthur JA<br>671 J, Mountjoy E, Sollis E, et<br>672 association studies, targe<br>673 47:D1005-D1012.<br>674 4. Bycroft C, Freeman C, Pet<br>675 0'Connell J, et al: The UK<br>676 2018, 562:203-209.<br>677 5. Sudlow C, Gal
- 
- 971 J, Mountjoy E, Sollis E, et al: The NHGRI-EBI GWAS Catalog of published genome-wide<br>
47. Bunchiov E, Sollis E, et al: The NHGRI-EBI GWAS Catalog of published genome-wide<br>
47. Bycroft C, Freeman C, Petkova D, Band G, El 672 association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res 20<br>
673 47:D1005-D1012.<br>
674 8 bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D, Dela<br>
675 0'Connell 673<br> **47:**D1005-D1012.<br> **47:D1005-D1012.**<br> **47:D1005-D1012.**<br> **574**<br> **4**. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D, Delanea<br>
O'Connell J, et al: **The UK Biobank resource with deep** 674 4. Bycroft C, Freeman<br>
675 0'Connell J, et al:<br>
676 2018, **562**:203-209<br>
677 5. Sudlow C, Gallach<br>
679 M, et al: **UK bioba<br>
680 6. Leitsalu L, Haller T<br>
681 L, et al: <b>Cohort Pro**<br>
682 *Int J Epidemiol* 201
- 
- 675 C'Connell J, et al: The UK Biobank resource with deep phenotyping and genomic data. Nature<br>676 2018, 562:203-209.<br>677 S. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landra O'Connell J, et al: **The UK Biobank resource with deep phenotyping and genomic data.** Nature<br>
2018, **562**:203-209.<br>
5. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray<br>
M, 677 5. Sudlow C, Gallacher<br>
678 M, et al: **UK biobanl<br>
679 complex diseases of<br>
680 6. Leitsalu L, Haller T, E<br>
681 L, et al: Cohort Profi<br>
682 Int J Epidemiol 2015** M, et al: UK biobank: an open access resource for identifying the causes of a wide range of<br>
679 complex diseases of middle and old age. *PLoS Med* 2015, 12:e1001779.<br>
680 6. Leitsalu L, Haller T, Esko T, Tammesoo ML, Alav 679 **Complex diseases of middle and old age.** *PLoS Med* 2015, **12**:e1001779.<br>
680 6. Leitsalu L, Haller T, Esko T, Tammesoo ML, Alavere H, Snieder H, Perola M, Ng PC, Magi R, Mil<br>
681 L, et al: Cohort Profile: Estonian Bi 680 6. Leitsalu L, Haller T, Esko T, Tammesoo ML, Alavere H, Snieder H, Perola N<br>681 L, et al: Cohort Profile: Estonian Biobank of the Estonian Genome Cente<br>*Int J Epidemiol* 2015, 44:1137-1147. 681 L, et al: Cohort Profile: Estonian Biobank of the Estonian Genome Center, University of Tartu.<br>
Int *J Epidemiol* 2015, 44:1137-1147.<br>
36<br>
36 682 Int J Epidemiol 2015, 44:1137-1147.  $\frac{1}{2}$  Int J Epidemiol 2015, 44:1157-1147.

It is made available under a COBBY-IMC-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.11.01.23297926;](https://doi.org/10.1101/2023.11.01.23297926) this version posted November 1, 2023. The copyright holder for this preprint

 $\frac{1}{2}$ Aavikko M, Kaunisto MA, et al: **FinnGen provides genetic insights from a well-phenotyped**<br>
685 Aavikko M, Kaunisto MA, et al: **FinnGen provides genetic insights from a well-phenotyped**<br>
685 Laisk T, Lepamets M, Koel M, Abn 685 isolated population. *Nature* 2023, 613:508-518.<br>
686 B. Laisk T, Lepamets M, Koel M, Abner E, Estonian Biobank Research T, Magi R: Genome-wide<br>
687 association study identifies five risk loci for pernicious anemia. *N* Souted population. Nature 2023, 013:508-516.<br>
686 8. Laisk T, Lepamets M, Koel M, Abner E, Estonian B<br>
687 ssociation study identifies five risk loci for perr<br>
689 EBRT, Piltonen TT, Laisk T, Kettunen J, Laivuori H:<br>
690 h association study identifies five risk loci for pernicious anemia. Nat Commun 2021, 12:376<br>
Fyrmi JS, Arffman RK, Pujol-Gualdo N, Kurra V, Morin-Papunen L, Sliz E, FinnGen Consortium<br>
EBRT, Piltonen TT, Laisk T, Kettunen J 688 9. Tyrmi JS, Arffman RK, Pujol-Gualdo N, Kurra V, Morin-Papunen L, Sliz E, FinnGen Consortium<br>689 EBRT, Piltonen TT, Laisk T, Kettunen J, Laivuori H: Leveraging Northern European population<br>690 history: novel low-frequ EBRT, Piltonen TT, Laisk T, Kettunen J, Laivuori H: Leveraging Northern European population<br>
689 EBRT, Piltonen TT, Laisk T, Kettunen J, Laivuori H: Leveraging Northern European population<br>
history: novel low-frequency var mistory: novel low-frequency variants for polycystic ovary syndrome. Hum Reprod 2022,<br>
691 history: novel low-frequency variants for polycystic ovary syndrome. Hum Reprod 2022,<br>
37:352-365.<br>
Alver M, Palover M, Saar A, Lal 691 **and Strate International Strate International Strate International Strate International Strate International Strategy A. Nikopensius<br>692 history: Novel M, Saar A, Lall K, Zekavat SM, Tonisson N, Leitsalu L, Reigo A, N** 692 10. Alver M, Palo<br>
693 Ainla T, et al:<br>
694 population-l<br>
695 11. King EA, Dav<br>
696 approved? R<br>
697 probability c<br>
698 12. Nelson MR, 1<br>
699 et al: The sup<br>
700 47:856-860. Alina T, et al: Recall by genotype and cascade screening for familial hypercholesterolemia in<br>
693 Ainla T, et al: Recall by genotype and cascade screening for familial hypercholesterolemia in<br>
694 population-based biobank 694 **books and cascade spaces and cascade screening** and case of the impact of genetic support twice as likely to be<br>695 approved? Revised estimates of the impact of genetic support for drug mechanisms on the<br>697 probabili bopulation-based biobalik from Estoma. Genet Med 2019, 21:1173-1180.<br>
695 11. King EA, Davis JW, Degner JF: **Are drug targets with genetic support twice**<br> **approved?** Revised estimates of the impact of genetic support for approved? Revised estimates of the impact of genetic support for drug mechanisms on<br>
probability of drug approval. PLoS Genet 2019, 15:e1008489.<br>
12. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, Floratos A For the incorporation of the incorporation of the incorporation of the incorect 2019, 15:e1008489.<br>
For the impact of the incorect  $P$ , Shen J, Nicoletti P, Shen Y, Floratos A, Sham PC, Li MJ, Wang<br>
et al: The support of h From MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, Flore et al: The support of human genetic evidence for approved di<br>
47:856-860.<br>
701 13. Reay WR, Cairns MJ: Advancing the use of genome-wide asso-<br>
702 repurposi 12. The support of human genetic evidence for approved drug indications. Nat Genet 2015,<br>
12. 856-860.<br>
13. Reay WR, Cairns MJ: Advancing the use of genome-wide association studies for drug<br>
13. Reay WR, Cairns MJ: Advanci 6999 et al: The support of human generic evidence for approved drug indications. Not denet 2015,<br>
700 47:856-860.<br>
701 13. Reay WR, Cairns MJ: Advancing the use of genome-wide association studies for drug<br>
702 repurposing. 701 13. Reay WR, Ca<br>
702 **repurposing.**<br>
703 14. Liu JZ, van Sc<br>
704 T, et al: **Asso<br>
705 highlight shape 15. Duerr RH**, Ta<br>
707 Regueiro M,<br>
708 **inflammator**<br>
709 16. Pidasheva S, repurposing. *Nat Rev Genet* 2021, 22:658-671.<br>
703 14. Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, Ripke S, Lee JC, Jostin.<br>
704 T, et al: Association analyses identify 38 susceptibility loci for infla To and the solid of the viener 2021, 22:658-671.<br>
703 14. Liu JZ, van Sommeren S, Huang H, Ng SC, Albert<br>
704 T, et al: **Association analyses identify 38 susception**<br>
706 15. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silver 704 1. Example 12. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and<br>
705 highlight shared genetic risk across populations. *Nat Genet* 2015, 47:979-986.<br>
706 15. Duerr RH, Taylor KD, 1705 highlight shared genetic risk across populations. Nat Genet 2015, 47:979-986.<br>
15. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C,<br>
1707 Regueiro M, Griffiths A, et al: A geno 15. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, A<br>
707 Regueiro M, Griffiths A, et al: **A genome-wide association study identifies IL231**<br> **16.** Pidasheva S, Trifari S, Phillips A, Hackne Regueiro M, Griffiths A, et al: **A genome-wide association study identifies IL23R as an**<br> **Regueiro M, Griffiths A, et al: A genome-wide association study identifies IL23R as an**<br> **Regueiro M, Griffiths A, et al: A genome**inflammatory bowel disease gene. *Science* 2006, **314**:1461-1463.<br>
709 16. Pidasheva S, Trifari S, Phillips A, Hackney JA, Ma Y, Smith A, Sohn SJ, Spits H, Little RD, E<br>
710 TW, et al: Functional studies on the IBD suscept 16. Pidasheva S, Trifari S, Phillips A, Hackney JA, Ma Y, Smith A, Sohn S<br>
16. Pidasheva S, Trifari S, Phillips A, Hackney JA, Ma Y, Smith A, Sohn S<br>
17. TV, et al: **Functional studies on the IBD susceptibility gene IL23R** The TW, et al: **Functional studies on the IBD susceptibility gene IL23R implicate reduced receptor**<br>
The protective genetic variant R381Q. PLoS One 2011, 6:e25038.<br>
Peyrin-Biroulet L, Ghosh S, Lee SD, Lee WJ, Griffith J, W 711 function in the protective genetic variant R381Q. *PLoS One* 2011, 6:e25038.<br>
712 T. Peyrin-Biroulet L, Ghosh S, Lee SD, Lee WJ, Griffith J, Wallace K, Berg S, Liao X, Panes J, Loftus E<br>
713 Jr., Louis E: Effect of ris 11 function in the protective genetic variant NSSTQ. Pross One 2011, 0.623038.<br>
12 17. Peyrin-Biroulet L, Ghosh S, Lee SD, Lee WJ, Griffith J, Wallace K, Berg S, Liao X<br>
12 17., Louis E: Effect of risankizumab on health-re 113 Ir., Louis E: **Effect of risankizumab on health-related quality of life in patients with Crohn's**<br>
114 **disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials.** Aliment<br>
115 *Pharmacol Ther* 2023, 113 Jr., Louis E: Effect of risankizumab on health-related quality of life in patients with Crohn's<br>
1214 disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials. Aliment<br>
1215 *Pharmacol Ther* 2023, **5** 214<br> *Pharmacol Ther* 2023, **57:**496-508.<br> **13.** Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagar<br>
Hisamatsu T, Lim A, et al: **Risankizumab as maintenance therapy for moderately to se** 115 Pharmacol Ther 2023, 37:496-908.<br>
716 18. Ferrante M, Panaccione R, Baert F,<br>
717 Hisamatsu T, Lim A, et al: **Risankizu**<br>
719 **controlled, withdrawal phase 3 FO<br>
720 19. Feagan BG, Sandborn WJ, Gasink C,<br>
721 Ll, Miao** Fisamatsu T, Lim A, et al: Risankizumab as maintenance therapy for moderately to severely<br>
This Hisamatsu T, Lim A, et al: Risankizumab as maintenance therapy for moderately to severely<br>
active Crohn's disease: results fro active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-<br>
719 controlled, withdrawal phase 3 FORTIFY maintenance trial. *Lancet* 2022, 399:2031-2046.<br>
720 19. Feagan BG, Sandborn WJ, Gasink active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-<br>
719 controlled, withdrawal phase 3 FORTIFY maintenance trial. *Lancet* 2022, 399:2031-2046.<br>
720 T9. Feagan BG, Sandborn WJ, Gasink 219 controlled, withdrawal phase 3 FORTIFT maintenance trial. Lancet 2022, 399:2031-2040.<br>
220 Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J<br>
221 Engl J Med 2016, 375:1946-1960.<br> 19. Fearly 10. Feagal BC, Ned 2016, 375:1946-1960.<br>
19. Feagl J Med 2016, 375:1946-1960.<br>
19. Feagl J Med 2016, 375:1946-1960.<br>
19. Feagan B, Dio LL, Miao Y, et al: Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N<br>
722 Engl J Med 2016, 375:1946-1960.<br>
723 20. Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, Zhernakova A, Stahl E, Viatte S, 22<br>
20. Eyre S, Bowes J, Diogo D, Lee A, Ba<br>
224 et al: **High-density genetic mappii**<br>
725 *Nat Genet* 2012, 44:1336-1340.<br>
21. Teslovich TM, Musunuru K, Smith<br>
727 Ripatti S, Chasman DI, Willer CJ, et<br>
728 **blood lipids.** et al: High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis.<br>
725 *Nat Genet* 2012, 44:1336-1340.<br>
726 21. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, Pirru 725 Nat Genet 2012, 44:1336-1340.<br>
726 21. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, Pirruccello JP,<br>
727 Ripatti S, Chasman DI, Willer CJ, et al: **Biological, clinical and population releva** 725 Mat Genet 2012, 44:1336-1340.<br>
726 21. Teslovich TM, Musunuru K, Smit<br>
727 Ripatti S, Chasman DI, Willer CJ,<br>
729 22. Ober C, Yao TC: **The genetics of**<br>
730 *Immunol Rev* 2011, **242:**10-30. 727 Ripatti S, Chasman DI, Willer CJ, et al: Biological, clinical and population relevance of 95 loci<br>
1728 Blood lipids. Nature 2010, 466:707-713.<br>
22. Ober C, Yao TC: The genetics of asthma and allergic disease: a 21st c 728 blood lipids. Nature 2010, 466:707-713.<br>
729 22. Ober C, Yao TC: The genetics of asthma and allergic disease: a 21st century perspective.<br>
Immunol Rev 2011, 242:10-30.<br>
37 728 blood lipids. Nature 2010, 466:707-713.<br>729 22. Ober C, Yao TC: **The genetics of asthma** a<br>730 *Immunol Rev* 2011, **242**:10-30.  $100$  22. Ober C,  $242:10-30$ .  $100$  Immunol Rev 2011, 242.10-30.

 $\frac{1}{2}$ The Consideration of candidate causal genes for asthma in susceptibility loci<br>
1732 20 Obeidat M, et al: Prioritization of candidate causal genes for asthma in susceptibility loci<br>
1733 24. Maurano MT, Humbert R, Rynes E, 233 derived from UK Biobank. Commun Biol 2021, 4:700.<br>
24. Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang H, Reynolds AP, Sandstro<br>
24. Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang H, Reynolds AP, 233 derived from OK Biobank. Comman Bior 2021, 4:700.<br>
734 24. Maurano MT, Humbert R, Rynes E, Thurman RE, Haug<br>
735 Qu H, Brody J, et al: **Systematic localization of common regulatory DNA.** Science 2012, **337:11**90-1195.<br> Qu H, Brody J, et al: **Systematic localization of common disease-associated variation in**<br> **1736** 25. Claussnitzer M, Dankel SN, Kim KH, Quon G, Meuleman W, Haugen C, Glunk V, Sousa IS, Beaudr<br>
1737 25. Claussnitzer M, Dan regulatory DNA. Science 2012, 337:1190-1195.<br>
736 regulatory DNA. Science 2012, 337:1190-1195.<br>
737 25. Claussnitzer M, Dankel SN, Kim KH, Quon G, Meuleman W, Haugen C, Glunk V, Sousa IS,<br>
1. Puviindran V, et al: FTO Obesi Figuratory DNA: Science 2012, 337.1150-1155.<br>
737 25. Claussnitzer M, Dankel SN, Kim KH, Quon G, Me<br>
1. Puviindran V, et al: **FTO Obesity Variant Circ**<br>
739 *Engl J Med* 2015, **373:**895-907.<br>
740 26. Mountjoy E, Schmidt EM 138 IL, Puviindran V, et al: **FTO Obesity Variant Circuitry and Adipocyte Browning in Humans.** N<br>
139 Engl J Med 2015, **373:** 895-907.<br>
139 Engl J Med 2015, **373:** 895-907.<br>
140 26. Mountjoy E, Schmidt EM, Carmona M, Schwa *Let*, Communism V, et al: FTO Obesity Variant Circuity and Adipocyte Browning in Humans. Neverty Fight J Med 2015, 373:895-907.<br>
740 26. Mountjoy E, Schmidt EM, Carmona M, Schwartzentruber J, Peat G, Miranda A, Fumis L, H 26. Mountjoy E, Schmidt EM, Carm<br>
741 J, Buniello A, Karim MA, et al: A<br>
742 genes at all published human C<br>
743 27. Smith GD, Ebrahim S: **'Mendelia**<br>
745 28. Davey Smith G, Hemani G: Men<br>
747 29. Richardson TG, Hemani G, 19929. Tarright Mountzentria Communication Systematically prioritize causal variants and<br>
1991 27. Smith GD, Ebrahim S: 'Mendelian randomization': can genetic epidemiology contribute to<br>
1992 28. Davey Smith G, Hemani G: M Figures at all published human GWAS trait-associated loci. Nat Genet 2021, 53:1527-1533.<br>
27. Smith GD, Ebrahim S: 'Mendelian randomization': can genetic epidemiology contribute to<br>
27. Smith GD, Ebrahim S: 'Mendelian rand For 2021, 33:1527-1533.<br>
27. Smith GD, Ebrahim S: 'Mendelian randomization': can genetic epidemiology contribute to<br>
27. Davey Smith G, Hemani G: Mendelian randomization: genetic epidemiology contribute to<br>
28. Davey Smith 27. Smith GD, Ebrahim S: **'Mendelian randomization': can genetic epidemiology contribute to**<br>
2744 understanding environmental determinants of disease? *Int J Epidemiol* 2003, 32:1-22.<br>
28. Davey Smith G, Hemani G: Mendeli 28. Davey Smith G, Hemani G: Mendelian randomization: genetic anchors for causal infere<br>
28. Davey Smith G, Hemani G: Mendelian randomization: genetic anchors for causal infere<br>
29. Richardson TG, Hemani G, Gaunt TR, Relto 22. Davey Smith G: A transcriptome-wide<br>
29. Richardson TG, Hemani G, Gaunt TR, Relton CL, Davey Smith G: A transcriptome-wide<br>
29. Richardson TG, Hemani G, Gaunt TR, Relton CL, Davey Smith G: A transcriptome-wide<br>
29. Mor 29. Richardson TG, Hemani G, Gaunt TR, Relton CL, Davey Smitl<br>
747 29. Richardson TG, Hemani G, Gaunt TR, Relton CL, Davey Smitl<br>
749 **Mendelian randomization study to uncover tissue-depend<br>
2014, 11.185.<br>
750 30. Hormozdi** Mendelian randomization study to uncover tissue-dependent regulatory mechanism<br>
T49. Mendelian randomization study to uncover tissue-dependent regulatory mechanism<br>
the human phenome. Nat Commun 2020, 11:185.<br>
T51. Pasaniu 149 **148 Mendelian randomization Study 11:185**<br>
1750 30. Hormozdiari F, van de Bunt M, Segre AV, Li X, Joo JWJ, Bilow M, Sul JH, Sankararaman S,<br>
1751 Pasaniuc B, Eskin E: Colocalization of GWAS and eQTL Signals Detects Ta 249<br>
2750 30. Hormozdiari F, van de Bunt M, Segre AV, Li X, Joo J'<br>
2751 Pasaniuc B, Eskin E: **Colocalization of GWAS and et**<br>
2752 *Genet* 2016, 99:1245-1260.<br>
2753 31. Giambartolomei C, Vukcevic D, Schadt EE, Franke L<br>
2 For Figure 2016, 99:1245-1260.<br>
751 Pasaniuc B, Eskin E: Colocalization of GWAS and eQTL Signals Detects Target Genes. Am<br>
752 Genet 2016, 99:1245-1260.<br>
31. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Fasanide B, Eskin E. Colocalization of GWAS and EQTL Signals Betects Target Genes. Am J Hum<br>752 Genet 2016, 99:1245-1260.<br>753 31. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, Plagnol V:<br>754 B For the Bayesian test for colocalisar<br>
753 31. Giambartolomei C, Vukcevic<br>
755 statistics. *PLoS Genet* 2014,<br>
756 32. Consortium GT, Laboratory<br>
757 groups-Analysis Working G,<br>
758 et al: **Genetic effects on ger**<br>
759 33. Bayesian test for colocalisation between pairs of genetic association studies using sum<br>
1755 Statistics. PLoS Genet 2014, 10:e1004383.<br>
2756 Statistics. PLoS Genet 2014, 10:e1004383.<br>
2757 Statistical Met<br>
2757 groups-Ana 755 statistics. *PLoS Genet* 2014, 10:e1004383.<br>
756 32. Consortium GT, Laboratory DA, Coordinating Center -Analysis Working G, Statistical Methods<br>
8757 groups-Analysis Working G, Enhancing Gg, Fund NIHC, Nih/Nci, Nih/Nhg 32. Consortium GT, Laboratory DA, Coordinati<br>
757 groups-Analysis Working G, Enhancing Gg,<br>
758 et al: **Genetic effects on gene expression** a<br>
759 33. Ndungu A, Payne A, Torres JM, van de Bun<br>
760 Analysis of Human Metabol groups-Analysis Working G, Enhancing Gg, Fund NIHC, Nih/Nci, Nih/Nhgri, Nih/Nimh, Nih/Nidi<br>
et al: Genetic effects on gene expression across human tissues. *Nature* 2017, 550:204-213.<br>
1759 33. Ndungu A, Payne A, Torres JM 758 et al: Genetic effects on gene expression across human tissues. *Nature* 2017, 550:204-213.<br>
759 33. Ndungu A, Payne A, Torres JM, van de Bunt M, McCarthy MI: **A Multi-tissue Transcriptome**<br> **Analysis of Human Metabol** 258 et al: Genetic effects on gene expression across human tissues. Nature 2017, 350.204-213.<br>
259 33. Mdungu A, Payne A, Torres JM, van de Bunt M, McCarthy MI: A Multi-tissue Transcriptome<br>
260 Analysis of Human Metabolit For Malysis of Human Metabolites Guides Interpretability of Associations Based on Multi-SNI<br>
Models for Gene Expression. Am J Hum Genet 2020, 106:188-201.<br>
261 Liu X, Finucane HK, Gusev A, Bhatia G, Gazal S, O'Connor L, Bu Models for Gene Expression. Am J Hum Genet 2020, 106:188-201.<br>
762 34. Liu X, Finucane HK, Gusev A, Bhatia G, Gazal S, O'Connor L, Bulik-Sullivan B, Wright FA, Sulliva<br>
763 PF, Neale BM, Price AL: Functional Architectures Models for Gene Expression. Am J Hum Genet 2020, 100.160-201.<br>
762 34. Liu X, Finucane HK, Gusev A, Bhatia G, Gazal S, O'Connor L, Bulik-Su<br>
763 PF, Neale BM, Price AL: Functional Architectures of Local and Dista<br>
Expressi 262 34. Liu X, Finucane HK, Gusev A, Bhatia G, Gazal S, O'Connor L, Bulik-Sullivan B, Wright FA, Sullivan<br>
263 PF, Neale BM, Price AL: Functional Architectures of Local and Distal Regulation of Gene<br>
264 Expression in Mult Expression in Multiple Human Tissues. Am J Hum Genet 2017, 100:605-616.<br>
2765 S. Consortium GT: Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis<br>
2766 multitissue gene regulation in humans. *Science* 20 Expression in Multiple Human Tissues. Am J Hum Genet 2017, 100:605-616.<br>
265 35. Consortium GT: Human genomics. The Genotype-Tissue Expression (GTEx) p<br>
multitissue gene regulation in humans. Science 2015, 348:648-660.<br>
26 multitissue gene regulation in humans. Science 2015, 348:648-660.<br>
T67 36. Connally NJ, Nazeen S, Lee D, Shi H, Stamatoyannopoulos J, Chun S, Cotsapas C, Cassa CA,<br>
Sunyaev SR: The missing link between genetic association multitissue gene regulation in humanis. Science 2015, 348:648-660.<br>
767 36. Connally NJ, Nazeen S, Lee D, Shi H, Stamatoyannopoulos J, Chun S, (<br>
769 11.<br>
770 37. Mostafavi H, Spence JP, Naqvi S, Pritchard JK: **Limited ove** Sunyaev SR: **The missing link between genetic association and regulatory function.** *Elife* 2<br> **11.**<br>
770 37. Mostafavi H, Spence JP, Naqvi S, Pritchard JK: **Limited overlap of eQTLs and GWAS hits du**<br> **171** systematic dif For Sunyaev SR: The missing link between genetic association and regulatory function. *Life 2022*,<br>
11. Mostafavi H, Spence JP, Naqvi S, Pritchard JK: **Limited overlap of eQTLs and GWAS hits due to**<br>
171 systematic differe 770 37. Mo:<br>771 syst<br>772 38. Less<br>773 E, e<br>773 E, e<br>775 39. Sme<br>776 Sob<br>777 fun Solution: The Systematic differences in discovery. *bioRxiv* 2022.<br>
1772 38. Lessard S, Gatof ES, Beaudoin M, Schupp PG, Sher F, Ali A, Prehar S, Kurita R, Nakamura Y, Baer<br>
1773 E, et al: An erythroid-specific ATP2B4 enha 38. Lessard S, Gatof ES, Beaudoin M, Schupp PG, Sher I<br>773 E, et al: **An erythroid-specific ATP2B4 enhancer m**<br>susceptibility. J Clin Invest 2017, 127:3065-3074.<br>775 39. Smemo S, Tena JJ, Kim KH, Gamazon ER, Sakabe NJ<br>776 E, et al: **An erythroid-specific ATP2B4 enhancer mediates red blood cell hydration and malaria**<br> **774** S9. Smemo S, Tena JJ, Kim KH, Gamazon ER, Sakabe NJ, Gomez-Marin C, Aneas I, Credidio FL,<br>
Sobreira DR, Wasserman NF, e 2774 susceptibility. *J Clin Invest* 2017, 127:3065-3074.<br>
2775 39. Smemo S, Tena JJ, Kim KH, Gamazon ER, Sakabe NJ, Gomez-Marin C, Aneas I, Credidio FL,<br>
275 Sobreira DR, Wasserman NF, et al: Obesity-associated variants w 3174 Susceptibility. J Chimnest 2017, 127.3065-3074.<br>
775 39. Smemo S, Tena JJ, Kim KH, Gamazon ER, Sakabe N<br>
Sobreira DR, Wasserman NF, et al: **Obesity-associ**<br>
functional connections with IRX3. Nature 2014, 5 Sobreira DR, Wasserman NF, et al: Obesity-associated variants within FTO form long-ran,<br>functional connections with IRX3. Nature 2014, 507:371-375.<br>The functional connections with IRX3. Nature 2014, 507:371-375. Functional connections with IRX3. Nature 2014, 507:371-375.<br>
Functional: Connections with IRX3. Nature 2014, 507:371-375. 777 functional connections with IRX3. Nature 2014, 507:371-375.

It is made available under a COBBY-IMC-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.11.01.23297926;](https://doi.org/10.1101/2023.11.01.23297926) this version posted November 1, 2023. The copyright holder for this preprint

 $\begin{array}{c} \n\text{1} \quad \text{2} \quad \text{3} \quad \text{4} \quad \text{5} \quad \text{6} \quad \text{6} \quad \text{7} \quad \text{8} \quad \text{8} \quad \text{9} \quad \text{1} \quad \$ 179 Langdon R, et al: **The MR-Base platform supports systematic causal inference across the**<br>
1790 Langdon R, et al: **The MR-Base platform supports systematic causal inference across the**<br>
1780 human phenome. *Elife* 2018, 1780 **human phenome.** *Elife* 2018, 7.<br>
1781 **41.** Nasser J, Bergman DT, Fulco CP, Guckelberger P, Doughty BR, Patwardhan TA, Jones TR, N,<br>
1782 TH, Ulirsch JC, Lekschas F, et al: Genome-wide enhancer maps link risk varian 180 **120 human phenome.** Elije 2018, 7.<br>
181 **120 11 Alman DT, Fulco CP,**<br>
182 **FIA, Ulirsch JC, Lekschas F, et al.**<br>
183 **genes.** Nature 2021, **593:**238-24<br>
184 **12.** McLaren W, Gil L, Hunt SE, Riat 1<br>
185 **Ensembl Varian** TH, Ulirsch JC, Lekschas F, et al: Genome-wide enhancer maps link risk variants to disease<br>
783 genes. Nature 2021, 593:238-243.<br>
784 42. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, Flicek P, Cunningham F: 783<br> **1783**<br> **1784**<br> **1784**<br> **1785**<br> **1785**<br> **1785**<br> **1785**<br> **1786**<br> **1786**<br> **1786**<br> **1786**<br> **1786**<br> **1786**<br> **1866**<br> **1787**<br> **1866**<br> **1866**<br> **1866**<br> **1877**<br> **1986**<br> **1877**<br> **1986**<br> **1877**<br> **1986**<br> **1886**<br> **1886**<br> **1877**<br> 283<br>
784 42. McLaren W, Gil L, Hunt SE, Riat HS,<br>
785 **Ensembl Variant Effect Predictor.**<br>
787 Abecasis GR, et al: Reference-base<br>
787 Abecasis GR, et al: Reference-base<br>
788 *Nat Genet* 2016, 48:1443-1448.<br>
790 for whole-Frame Matter School (1722)<br>
785 Ensembl Variant Effect Predictor. Genome Biol 2016, 17:122.<br>
786 43. Loh PR, Danecek P, Palamara PF, Fuchsberger C, Y AR, H KF, Schoenherr S, Forer L, McCar<br>
787 Abecasis GR, et al: Referenc 2020.<br>
2020. Abecasis GR, et al: Reference-based phasing using the Haplot<br>
201788 Mat Genet 2016, 48:1443-1448.<br>
2018. Abecasis GR, et al: Reference-based phasing using the Haplot<br>
2016. A8:1443-1448.<br>
2029 Mat Genet 2005, Abecasis GR, et al: **Reference-based phasing using the Haplotype Reference Consortium pane**<br>
788 *Not Genet 2016*, **48:**1443-1448.<br>
789 44. Browning SR, Browning BL: **Rapid and accurate haplotype phasing and missing-data i** 788 Mat Genet 2016, 48:1443-1448.<br>
788 Nat Genet 2016, 48:1443-1448.<br>
789 44. Browning SR, Browning BL: Rapid and accurate haplotype phasing and missing-data inference<br>
for whole-genome association studies by use of locali Mat Genet 2016, 48:1443-1446.<br>
789 44. Browning SR, Browning BL: **Rapi<br>
for whole-genome association**<br>
791 *Genet* 2007, **81**:1084-1097.<br>
793 46. Maintainer BP: liftOver: Changir<br>
794 *package version 1180* 2021.<br>
795 47. From The Terming School of the Hillips AD, Shiel JA, Thomas NS, Abeysinghe S, Krawczak M,<br>
1992 45. Maintainer BP: liftOver: Changing genomic coordinate systems with rtracklayer::liftOver. R<br>
1992 46. Maintainer BP: liftOv For whole-genome association statics by use of localized haplotype clustering. Am J Hum<br>
791 *Genet* 2007, **81:1084-1097**.<br>
792 45. Maintainer BP: lift**Over: Changing genomic coordinate systems with rtracklayer::liftOver.** 191 Genet 2007, **01.1004 1097.**<br>
192 45. team P-U: **https://pan.ukbb**<br>
193 46. Maintainer BP: **liftOver: Change 2021.**<br>
195 47. Stein D, Bayrak CS, Wu Y, St.<br>
196 **prediction of pathogenic gangle 1948.**<br>
197 feature set. 793 46. Maintainer BP: liftOver: Changing genomic coordinate<br>
794 package version 1180 2021.<br>
795 47. Stein D, Bayrak CS, Wu Y, Stenson PD, Cooper DN, Schle<br> **prediction of pathogenic gain- and loss-of-function varior feat** 203 46. Maintainer Br: intover: Changing genomic coordinate systems with ritackiayer:.intover. *N*<br>
2021. 2021. Stein D, Bayrak CS, Wu Y, Stenson PD, Cooper DN, Schlessinger A, Itan Y: Genome-wide<br>
2021. 2009 prediction of Machine Version 1180 2021.<br>
795 47. Stein D, Bayrak ÇS, Wu Y, Ste<br>
797 feature set. bioRxiv 2022.<br>
798 48. Stenson PD, Ball EV, Mort M,<br>
799 Cooper DN: **Human Gene M**<br>
800 581.<br>
801 49. Sun BB, Maranville JC, Peters<br>
802 S Prediction of pathogenic gain- and loss-of-function variants from ensemble learning of<br>
The feature set. bioRxiv 2022.<br>
The feature set. bioRxiv 2022.<br>
Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, Abeysin Frediction of pathology of the U.S. Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, Abeysinghe S, Krawczak M,<br>
Cooper DN: **Human Gene Mutation Database (HGMD): 2003 update.** Hum Mutat 2003, **21:**577-<br>
581. S Feature set. bioNAV 2022.<br>
798 48. Stenson PD, Ball EV, Mort<br>
799 Cooper DN: **Human Gene**<br>
800 581.<br>
801 49. Sun BB, Maranville JC, Pet.<br>
802 Surendran P, et al: **Genom**<br>
803 50. Chen L, Ge B, Casale FP, Va<br>
804 al: **Genet** Cooper DN: **Human Gene Mutation Database (HGMD): 2003 update.** Hum Mutat 2003, 2.<br>
581. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, Burgess S, Jiang T, Paige<br>
802 Surendran P, et al: Genomic atlas o 2003 Cooper DN: Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 2003, 21:377-<br>
301 49. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, Burgess S, Jiang T, Paige E,<br>
302 Surendran P, et al: 801 49. Sun F<br>
802 Surer<br>
803 50. Chen<br>
804 al: **G**<br>
805 2016<br>
806 51. Vosa<br>
807 R, Ya<br>
808 polyg<br>
808 polyg<br>
809 52. Kerin Surendran P, et al: Genomic atlas of the human plasma proteome. Nature 2018, 558:73-79.<br>
Surendran P, et al: Genomic atlas of the human plasma proteome. Nature 2018, 558:73-79.<br>
Chen L, Ge B, Casale FP, Vasquez L, Kwan T, Surendran P, et al: Genomic atlas of the human plasma proteome. Nature 2018, 338:73-79.<br>
803 So. Chen L, Ge B, Casale FP, Vasquez L, Kwan T, Garrido-Martin D, Watt S, Yan Y, Kundu K, Ecker S<br>
al: Genetic Drivers of Epigene al: **Genetic Drivers of Epigenetic and Transcriptional Variation in Human Immune Cells.** *Cell*<br>
2016, **167**:1398-1414 e1324.<br>
806 51. Vosa U, Claringbould A, Westra HJ, Bonder MJ, Deelen P, Zeng B, Kirsten H, Saha A, Kreu 805<br>
805 2016, 167:1398-1414 e1324.<br>
806 51. Vosa U, Claringbould A, Westra HJ, Bonder MJ, Deelen P, Zeng B, Kirsten H, Saha A, Kreuzhub.<br>
807 8. Yosa U, Claringbould A, Westra HJ, Bonder MJ, Deelen P, Zeng B, Kirsten H, S 806 51. Vosa U, Claringbould A, West<br>807 R, Yazar S, et al: **Large-scale c**<br>808 **polygenic scores that regulat**<br>809 52. Kerimov N, Hayhurst JD, Peik<br>810 Kuzmin I, Trevanion SJ, et al: *Land splicing quantitative trai*<br>812 807 R, Yazar S, et al: Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and<br>
808 polygenic scores that regulate blood gene expression. *Nat Genet* 2021, 53:1300-1310.<br>
809 S2. Kerimov N, Hayhurst **Example 19 Solution Sol** Bolygenic scores that regulate blood gene expression. Met denet 2021, 33:1300-1310.<br>
809 52. Kerimov N, Hayhurst JD, Peikova K, Manning JR, Walter P, Kolberg L, Samovica M, Sakth<br>
810 Kuzmin I, Trevanion SJ, et al: **A comp** Kuzmin I, Trevanion SJ, et al: **A compendium of uniformly processed human gene expression**<br> **811** and splicing quantitative trait loci. Nat Genet 2021, 53:1290-1299.<br>
812 53. Buil A, Brown AA, Lappalainen T, Vinuela A, Dav 811 and splicing quantitative trait loci. Not Genet 2021, 53:1290-1299.<br>
812 Buil A, Brown AA, Lappalainen T, Vinuela A, Davies MN, Zheng HF, Richards JB, Glass D, Small K<br>
813 Durbin R, et al: Gene-gene and gene-environme and splicing quantitative trait loci. Md Genet 2021, 33:1290-1299.<br>
812 53. Buil A, Brown AA, Lappalainen T, Vinuela A, Davies MN, Zheng HF, R<br>
813 Durbin R, et al: Gene-gene and gene-environment interactions det<br>
sequence Durbin R, et al: Gene-gene and gene-environment interactions detected by transcriptome<br>
sequence analysis in twins. Nat Genet 2015, 47:88-91.<br>
815 54. Jaffe AE, Straub RE, Shin JH, Tao R, Gao Y, Collado-Torres L, Kam-Thong state of the human cortex transcriptome and interactions of the human cortex transcriptome illuminate<br>
815 Bure al: Developmental and genetic regulation of the human cortex transcriptome illuminate<br>
817 Surface et al: Deve Sequence analysis in twins. Not Genet 2015, 47:88-91.<br>
815 54. Jaffe AE, Straub RE, Shin JH, Tao R, Gao Y, Collado-Torre<br>
et al: **Developmental and genetic regulation of the hur**<br>
schizophrenia pathogenesis. *Nat Neurosci* et al: Developmental and genetic regulation of the human cortex transcriptome illuminate<br>
schizophrenia pathogenesis. Nat Neurosci 2018, 21:1117-1125.<br>
Schmiedel BJ, Singh D, Madrigal A, Valdovino-Gonzalez AG, White BM, Za 817 schizophrenia pathogenesis. Nat Neurosci 2018, 21:1117-1125.<br>818 S5. Schmiedel BJ, Singh D, Madrigal A, Valdovino-Gonzalez AG, White BM, Zapardiel-Gonzalo J, H<br>819 Altay G, Greenbaum JA, McVicker G, et al: I**mpact of G** Schmiedel BJ, Singh D, Madrigal A, Valdovino-Gonzalez AG, Whit<br>
818 55. Schmiedel BJ, Singh D, Madrigal A, Valdovino-Gonzalez AG, Whit<br>
820 Immune Cell Gene Expression. *Cell* 2018, 175:1701-1715 e1716.<br>
821 56. Ng B, Whit Altay G, Greenbaum JA, McVicker G, et al: **Impact of Genetic Polymorphisms on Human**<br> **S20**<br> **S21** 56. Ng B, White CC, Klein HU, Sieberts SK, McCabe C, Patrick E, Xu J, Yu L, Gaiteri C, Bennett DA, et<br>
al: An **xQTL** map in 820 **Altay G, Greenbaum C, Greenbaum C, Greenbaum 2018, 175:1701-1715** e1716.<br>
821 56. Ng B, White CC, Klein HU, Sieberts SK, McCabe C, Patrick E, Xu J, Yu L, Gaiteri C, Bennett D<br>
822 al: **An xQTL map integrates the genet** 820 Immune Cell Gene Expression. Cell 2016, 173.1701-1715 e1716.<br>821 56. Ng B, White CC, Klein HU, Sieberts SK, McCabe C, Patrick E, Xu J, \<br>al: An xQTL map integrates the genetic architecture of the huma<br>epigenome. Nat Ne 822 al: An xQTL map integrates the genetic architecture of the human brain's transcriptome and<br>epigenome. Nat Neurosci 2017, 20:1418-1426. al: An xQTL map integrates the genetic architecture of the human brain's transcriptome and<br>epigenome. Nat Neurosci 2017, 20:1418-1426.<br>Epigenome. Nat Neurosci 2017, 20:1418-1426. 823 epigenome. Nat Neurosci 2017, 20:1418-1426.

It is made available under a COBBY-IMC-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.11.01.23297926;](https://doi.org/10.1101/2023.11.01.23297926) this version posted November 1, 2023. The copyright holder for this preprint

i<br>C<br>C<br>C 825 T, Romano L, Planchon A, et al: Passive and active DNA methylation and the interplay with<br>825 genetic variation in gene regulation. *Elife* 2013, 2:e00523.<br>827 58. van de Bunt M, Manning Fox JE, Dai X, Barrett A, Grey 826 Seperatic variation in gene regulation. *Elife* 2013, 2:e00523.<br>
827 S8. van de Bunt M, Manning Fox JE, Dai X, Barrett A, Grey C, Li L, Bennett AJ, Johnson PR, Rajotte<br>
828 RV, Gaulton KJ, et al: **Transcript Expression** 827 58. van de Bunt M, Manning Fox JE, Dai X, Barrett A, Grey C, Li<br>828 RV, Gaulton KJ, et al: **Transcript Expression Data from Hum**<br>**629 From Genome-Wide Association Studies for Type 2 Diabet<br>830 Downstream Effectors.** *PL* RV, Gaulton KJ, et al: **Transcript Expression Data from Human Islets Links Regulatory Signals**<br> **829 Experiment Mind Association Studies for Type 2 Diabetes and Glycemic Traits to Their**<br> **830 Experiment Effectors.** *P* From Genome-Wide Association Studies for Type 2 Diabetes and Glycemic Traits to Their<br>
Bason K, Rodrigues J, Mukhopadhyay S, Knights AJ, Mann AL, Kundu K, Consortium H, Hale C,<br>
Bason K, Rodrigues J, Mukhopadhyay S, Knight 830 **Downstream Effectors.** *PLoS Genet* 2015, 11:e1005694.<br>
831 59. Alasoo K, Rodrigues J, Mukhopadhyay S, Knights AJ, Mann AL, Kundu K, Consortium H, Hale<br>
832 Dougan G, Gaffney DJ: **Shared genetic effects on chromatin a** Bow Bownstream Effectors. PEBS Genet 2015, 11:e1005054.<br>
831 59. Alasoo K, Rodrigues J, Mukhopadhyay S, Knights AJ, Man<br>
Dougan G, Gaffney DJ: **Shared genetic effects on chromation**<br>
for enhancer priming in immune response Dougan G, Gaffney DJ: **Shared genetic effects on chromatin and gene expression indicate a re**<br> **833 60.** Taylor DL, Jackson AU, Narisu N, Hemani G, Erdos MR, Chines PS, Swift A, Idol J, Didion JP, Wel<br>
835 RP, et al: Int For enhancer priming in immune response. Nat Genet 2018, 50:424-431.<br>
834 60. Taylor DL, Jackson AU, Narisu N, Hemani G, Erdos MR, Chines PS, Swift A, Idol J, Didion JP, Welch<br>
835 RP, et al: Integrative analysis of gene e 834 60. Taylor DL, Jackson AU, Narisu N, Hemani G, Erdos MR, Chines PS, Swift A, I<br>835 RP, et al: Integrative analysis of gene expression, DNA methylation, phys<br>836 genetic variation in human skeletal muscle. *Proc Natl Ac* 835 RP, et al: Integrative analysis of gene expression, DNA methylation, physiological traits, and<br>836 genetic variation in human skeletal muscle. *Proc Natl Acad Sci U S A* 2019, 116:10883-10888.<br>837 61. Lepik K, Annilo T 836 Superitic variation in human skeletal muscle. Proc Natl Acad Sci U S A 2019, 116:10883-10888.<br>
837 Eepik K, Annilo T, Kukuskina V, e QC, Kisand K, Kutalik Z, Peterson P, Peterson H: C-reactive<br>
838 protein upregulates 837 61. Lepik K, Annilo T, Kukuskina V, e QC, Kisand K, Kutalik Z, Peterson P, Peterson H: C-reactive<br>838 protein upregulates the whole blood expression of CD59 - an integrative analysis. *PLoS*<br>839 *Comput Biol* 2017, 13: Protein upregulates the whole blood expression of CD59 - an integrative analysis. PLoS<br>
839 *Comput Biol* 2017, 13:e1005766.<br>
840 62. Quach H, Rotival M, Pothlichet J, Loh YE, Dannemann M, Zidane N, Laval G, Patin E, Harma Brotein upregulates the whole blood expression of CD33 - an integrative analysis. PLoS<br>
839 Comput Biol 2017, 13:e1005766.<br>
840 62. Quach H, Rotival M, Pothlichet J, Loh YE, Dannemann M, Zidane N, Laval G, Patin E, Harm<br>
8 Example Biol 2017, 13:e1005766.<br>
840 62. Quach H, Rotival M, Pothlichet J,<br>
841 Lopez M, et al: **Genetic Adaptatic<br>
Human Populations.** Cell 2016, 1<br>
843 63. Nedelec Y, Sanz J, Baharian G, Szp<br>
844 Hebert S, et al: **Geneti** 19841<br>
841 Lopez M, et al: Genetic Adaptation and Neandertal Admixture Shaped the Immune System of<br>
842 Human Populations. *Cell* 2016, 167:643-656 e617.<br>
843 Hebert S, et al: Genetic Ancestry and Natural Selection Drive P Human Populations. *Cell* 2016, 167:643-656 e617.<br>
843 63. Nedelec Y, Sanz J, Baharian G, Szpiech ZA, Pacis A, Dumaine A, Grenier JC, Freiman A, Sams AJ,<br>
844 Hebert S, et al: Genetic Ancestry and Natural Selection Drive P Manham Populations. Cell 2016, 167:643-656 e617.<br>
843 63. Nedelec Y, Sanz J, Baharian G, Szpiech ZA, Pacis A, I<br>
Hebert S, et al: **Genetic Ancestry and Natural Selec<br>
1845 Immune Responses to Pathogens. Cell 2016, 167:6<br>
8** Example 18. Nedert S, et al: Genetic Ancestry and Natural Selection Drive Population Differences in<br>
1845 Immune Responses to Pathogens. Cell 2016, 167:657-669 e621.<br>
1846 64. Panopoulos AD, D'Antonio M, Benaglio P, Willia 845<br>
Immune Responses to Pathogens. *Cell* 2016, 167:657-669 e621.<br>
846 64. Panopoulos AD, D'Antonio M, Benaglio P, Williams R, Hashem SI, Schuldt BM, DeBoever (<br>
847 AD, Garcia M, Nelson BC, et al: **iPSCORE: A Resource of** miniume Responses to Pathogens. Cell 2016, 107:657-669 e621.<br>
846 64. Panopoulos AD, D'Antonio M, Benaglio P, Williams R, Hashem SI,<br>
AD, Garcia M, Nelson BC, et al: **iPSCORE: A Resource of 222 iPSC**<br> **Characterization of** 64. Panopoulos AD, D'Antonio M, Benaglio P, Williams R, Hashem SI, Schuldt BM, DeBoever C, Arias<br>
847 AD, Garcia M, Nelson BC, et al: **iPSCORE: A Resource of 222 iPSC Lines Enabling Functional**<br> **Characterization of Geneti** 848<br> **Characterization of Genetic Variation across a Variety of Cell Types.** Stem Cell Reports 201<br>
849<br>
8:1086-1100.<br>
Pashos EE, Park Y, Wang X, Raghavan A, Yang W, Abbey D, Peters DT, Arbelaez J, Hernandez<br>
851<br>
852<br>
852 Characterization of Genetic Variation across a Variety of Centrypes. Stem Centreports 2017,<br>
849 8:1086-1100.<br>
850 65. Pashos EE, Park Y, Wang X, Raghavan A, Yang W, Abbey D, Peters DT, Arbelaez J, Hernandez M<br>
851 Kuperwa 850 65. Pashos EE, Pal<br>
851 Kuperwasser I<br>
852 **Cells Reveal F<br>
853 20:558-570 e5<br>
854 66. Kilpinen H, Go<br>
855 Culley OJ, et a<br>
856 Mature 2017,<br>
857 67. Lappalainen T<br>
858 M, Kurbatova** Kuperwasser N, et al: Large, Diverse Population Cohorts of hiPSCs and Derived Hepatocyte-lik<br>
852 Cells Reveal Functional Genetic Variation at Blood Lipid-Associated Loci. Cell Stem Cell 2017,<br>
20:558-570 e510.<br>
66. Kilpin Calls Reveal Functional Genetic Variation at Blood Lipid-Associated Loci. Cell Stem Cell 2017,<br>
852 Cells Reveal Functional Genetic Variation at Blood Lipid-Associated Loci. Cell Stem Cell 2017,<br>
854 66. Kilpinen H, Goncal Eens Reveal Functional Genetic Variation at Blood Lipid-Associated Loci. Cell Stem Cell 2017,<br>
853 20:558-570 e510.<br>
854 66. Kilpinen H, Goncalves A, Leha A, Afzal V, Alasoo K, Ashford S, Bala S, Bensaddek D, Casale FP,<br>
2 854 66. Kilpinen H, Goncal<br>855 Culley OJ, et al: Co<br>856 *Nature* 2017, **546:**<br>857 67. Lappalainen T, Sar<br>858 M, Kurbatova N, G<br>860 68. Hoffman GE, Bend<br>861 ME, Johnson JS, G<br>862 epigenomic data f Culley OJ, et al: **Common genetic variation drives molecular heterogeneity in human iPSCs.**<br>
856 Mature 2017, **546:** 370-375.<br>
857 67. Lappalainen T, Sammeth M, Friedlander MR, t Hoen PA, Monlong J, Rivas MA, Gonzalez-Port Nature 2017, 546:370-375.<br>
857 67. Lappalainen T, Sammeth M, Friedlander MR, t Hoen PA, Monlong J, Rivas MA, Gonzalez-Porta<br>
858 M, Kurbatova N, Griebel T, Ferreira PG, et al: **Transcriptome and genome sequencing uncoverse** 857 67. Lappalainen T, Sammeth M,<br>858 M, Kurbatova N, Griebel T, I<br>859 functional variation in hum<br>860 68. Hoffman GE, Bendl J, Volou<br>861 ME, Johnson JS, Girdhar K, 6<br>862 epigenomic data for Schizo<br>863 69. Guelfi S, D'Sa K M, Kurbatova N, Griebel T, Ferreira PG, et al: **Transcriptome and genome sequencing uncover**<br>
858 M, Kurbatova N, Griebel T, Ferreira PG, et al: **Transcriptome and genome sequencing uncover**<br>
860 **68.** Hoffman GE, Bendl J, 1985 85 Munctional variation in humans. Nature 2013, 501:506-511.<br>
19860 88. Hoffman GE, Bendl J, Voloudakis G, Montgomery KS, Sloofman L, Wang YC, Shah HR, Hauberg<br>
19861 1996, Iohnson JS, Girdhar K, et al: CommonMind Con 68. Hoffman GE, Bendl J, Voloudakis G, Montgomery KS, Sloofm<br>
860 68. Hoffman GE, Bendl J, Voloudakis G, Montgomery KS, Sloofm<br>
862 **epigenomic data for Schizophrenia and Bipolar Disorder.** Sc<br>
863 69. Guelfi S, D'Sa K, Bo ME, Johnson JS, Girdhar K, et al: **CommonMind Consortium provides transcriptomic and**<br> **862 69.** Guelfi S, D'Sa K, Botia JA, Vandrovcova J, Reynolds RH, Zhang D, Trabzuni D, Collado-Torres L,<br> **864** Thomason A, Quijada L epigenomic data for Schizophrenia and Bipolar Disorder. Sci Data 2019, 6:180.<br>
862 epigenomic data for Schizophrenia and Bipolar Disorder. Sci Data 2019, 6:180.<br>
864 Guelfi S, D'Sa K, Botia JA, Vandrovcova J, Reynolds RH, epigenomic data for Schizophrenia and Bipolar Bisorder. Sci Ddid 2019, 0.160.<br>
863 69. Guelfi S, D'Sa K, Botia JA, Vandrovcova J, Reynolds RH, Zhang D, Trabzuni D, Colla<br>
864 Thomason A, Quijada Leyton P, et al: **Regulator** 69. Guelfi S, D'Sa K, Botia JA, Vandrovcova J, Reynolds RH, Zhang D, Trabzuni D, Collado-Torres L,<br>
864 Thomason A, Quijada Leyton P, et al: **Regulatory sites for splicing in human basal ganglia are**<br>
865 **enriched for dis** enriched for disease-relevant information. Nat Commun 2020, 11:1041.<br>
Thomas A, Calvert F, Hammond TR, Knights A, Panousis N, Park JS,<br>
Schwartzentruber J, Liu J, Kundu K, et al: A map of transcriptional heterogeneity and 2086 2009<br>
866 70. Young AMH, Kumasaka N, Calvert F, Hammond TR, Knights A, Panousis N,<br>
867 Schwartzentruber J, Liu J, Kundu K, et al: **A map of transcriptional hetero**<br> **9868** variation in human microglia. Nat Genet 2021 Schwartzentruber J, Liu J, Kundu K, et al: A map of transcriptional heterogeneity a<br>
Ses<br>
268 variation in human microglia. Nat Genet 2021, 53:861-868.<br>
269 71. Consortium GT: The GTEx Consortium atlas of genetic regulator 868 variation in human microglia. Not Genet 2021, 53:861-868.<br>869 variation in human microglia. Not Genet 2021, 53:861-868.<br>870 Science 2020, 369:1318-1330.<br>870 Science 2020, 369:1318-1330. Second Variation in human microglia. Nat Genet 2021, 33:861-868.<br>869 71. Consortium GT: **The GTEx Consortium atlas of genetic regul**<br>870 Science 2020, **369**:1318-1330. 870 Science 2020, **369**:1318-1330.<br>40 870 Science 2020, 369:1318-1330.



